1
|
Protonotarios A, Barriales-Villa R, Antoniades L, Mogensen J, Garcia-Pavia P, Wahbi K, Biagini E, Anastasakis A, Tsatsopoulou A, Zorio E, Gimeno JR, Garcia-Pinilla JM, Sinagra G, Bauce B, Elliott PM. Risk stratification in Arrhythmogenic Right Ventricular Cardiomyopathy: the impact of genotype on the 2019 ARVC risk calculator. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1752] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is associated with sudden cardiac death (SCD). The 2019 ARVC risk model has been proposed as a method to quantify arrhythmic risk, but the impact of genotype its performance has not been addressed.
Purpose
To study arrhythmic outcomes in patients with ARVC and the performance of the 2019 ARVC risk model in predefined genetic subgroups.
Methods
This is an international, retrospective observational cohort study on consecutively evaluated patients with ARVC recruited from 17 centres in 7 countries. Inclusion criteria were: (i) a definite diagnosis of ARVC according to the 2010 Task Force Criteria; (ii) no history of sustained ventricular arrhythmia (VA) prior to first assessment at the participating centre; (iii) a follow up period of ≥1 month; (iv) age of diagnosis ≥14 years. Sustained ventricular arrhythmia (sustained ventricular tachycardia, appropriate implantable cardioverter defibrillator intervention, aborted SCD, or SCD) comprised the primary outcome (VA). Discriminative ability was assessed by Uno's concordance index (c-statistic) and calibration with the calibration plot slope. Fine-Gray regression was used to model the impact of clinical predictors on the arrhythmic outcome, in the context of competing risks (heart transplantation and non-arrhythmic death). The cumulative probability and 95% confidence intervals (95% CI) for the occurrence of an outcome were estimated using the Aalen-Johansen estimate in order to take into account competing risks.
Results
The study cohort comprised 554 ARVC patients. During a median follow-up of 6.0 [3.1,12.5] years, 100 patients (18%) experienced VA (Figure). Risk estimates for VA using the 2019 ARVC risk model showed good discriminative ability (c-statistic 0.75 (95% CI 0.70–0.81)) but with overestimation of risk (slope 0.46 (95% CI 0.33–0.63)). The ARVC risk model was compared in 4 gene groups: PKP2 (n=118, 21%); DSP (n=79, 14%); other desmosomal (n=59, 11%); and gene elusive (n=160, 29%). Discrimination and calibration were highest for PKP2 [c-statistic 0.83 (95% CI 0.75–0.91); calibration slope 0.67 (95% CI 0.40–1.04)] and lowest for the gene elusive group [c-statistic 0.65 (95% CI 0.57–0.74); calibration slope 0.26 (95% CI 0.06–0.49)]. Univariable analyses revealed variable performance of individual clinical risk markers in the different gene groups (see heatmap of hazard ratios and statistical significance in Figure). For example, RV dimensions and systolic function are significant risk markers in PKP2 but not in DSP patients and the opposite is true of LV systolic function (Figure).
Conclusion
The 2019 ARVC risk model performs reasonably well in gene positive ARVC, (particularly for PKP2) but is more limited in gene elusive patients. Genotype specific risk factors should be considered in ARVC patients.
Funding Acknowledgement
Type of funding sources: Foundation. Main funding source(s): British Heart Foundation
Collapse
Affiliation(s)
| | - R Barriales-Villa
- Institute of Biomedical Research of La Coruna (INIBIC) , A Coruna , Spain
| | | | - J Mogensen
- Aalborg University Hospital , Aalborg , Denmark
| | - P Garcia-Pavia
- Puerta de Hierro Majadahonda University Hospital, Majadahonda , Madrid , Spain
| | - K Wahbi
- Cochin APHP Site of Paris Centre University Hospital , Paris , France
| | - E Biagini
- University Hospital of Bologna S. Orsola-Malpighi Polyclinic , Bologna , Italy
| | | | - A Tsatsopoulou
- Yannis Protonotarios Medical Center of Naxos , Naxos , Greece
| | - E Zorio
- University Hospital y Politecnico La Fe , Valencia , Spain
| | - J R Gimeno
- Virgin of the Arrixaca University Clinical Hospital , Murcia , Spain
| | | | - G Sinagra
- University of Trieste , Trieste , Italy
| | - B Bauce
- University of Padova , Padua , Italy
| | - P M Elliott
- University College London , London , United Kingdom
| |
Collapse
|
2
|
Witteles R, Sultan MB, Gundapaneni B, Garcia-Pavia P. Atrial fibrillation as a prognostic factor for all-cause mortality in patients with transthyretin amyloid cardiomyopathy. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.861] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction
Atrial fibrillation (afib) and flutter (aflutter) are among the most common manifestations of transthyretin amyloid cardiomyopathy (ATTR-CM) [1–3]. Studies have suggested that afib does not influence mortality [3–6]. Tafamidis was approved for the treatment of ATTR-CM based on the landmark, placebo-controlled, Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT), where all-cause mortality was a primary efficacy outcome [7].
Purpose
Evaluate whether afib/aflutter was prognostic for all-cause mortality in ATTR-ACT.
Methods
ATTR-ACT was a multinational, Phase 3, randomized study of patients with ATTR-CM receiving tafamidis meglumine (80 or 20 mg) or placebo over 30 months. This analysis describes the characteristics of patients with and without current/historical afib/aflutter at the baseline of ATTR-ACT. Current/historical afib/aflutter was then evaluated as an independent prognostic factor for all-cause mortality using Cox proportional hazards modelling.
Results
The 314/441 (71%) patients in ATTR-ACT with current/historical afib/aflutter were older, more commonly male, and White than those without (Table 1). A higher proportion of patients with current/historical afib/aflutter were NYHA class III and had a wild-type genotype than those without. Median 6MWT distance and the proportion of patients with preserved left ventricular ejection fraction (≥50%) were lower, GLS was less negative, and NT-proBNP and BUN were higher among those with current/historical afib/aflutter vs those without.
In ATTR-ACT, treatment, genotype, and NYHA class were included in the pre-specified Cox proportional hazards model assessing all-cause mortality. Once current/historical afib/aflutter was added to this model, all variables were found to be significant independent predictors of all-cause mortality (P<0.05; Table 2). The risk of mortality was 45% higher (hazard ratio = 0.55 [95% CI: 0.37, 0.82]) among patients with current/historical afib/aflutter than in those without. In an expanded stepwise model selection analysis including 23 baseline demographic and clinical covariates, current/historical afib/aflutter was not a significant independent predictor. This model showed BUN and NT-proBNP concentrations, 6MWT distance, genotype, treatment, and GLS to be significant independent prognostic factors for all-cause mortality (P<0.01; Table 2).
Conclusions
Patients in ATTR-ACT with ATTR-CM and current/historical afib/aflutter were older, more likely to be male, have a wild-type genotype, and more advanced heart failure than those without. A Cox model including treatment, genotype, and NYHA class identified current/historical afib/aflutter as a significant independent predictor of all-cause mortality. In an expanded stepwise selection model current/historical afib/aflutter remained important but was less prognostic compared to other covariates. Overall, these results demonstrate the importance of afib/aflutter in patients with ATTR-CM.
Funding Acknowledgement
Type of funding sources: Private company. Main funding source(s): This study was sponsored by Pfizer.
Collapse
Affiliation(s)
- R Witteles
- Stanford University School of Medicine , Stanford , United States of America
| | - M B Sultan
- Pfizer Inc. , New York , United States of America
| | | | - P Garcia-Pavia
- Hospital Universitario Puerta de Hierro Majadahonda, CIBERCV, and Universidad Francisco de Vitoria , Madrid , Spain
| |
Collapse
|
3
|
Lalaguna L, Lopez-Olaneta M, Villalba-Orero M, Rey-Martin A, Garcia-Pavia P, Lara-Pezzi E. Therapeutic potential of wild type TMEM43 overexpression in a mouse model of arrhythmogenic cardiomyopathy type 5. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2985] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background and purpose
Arrhythmogenic cardiomyopathy type 5 (ACM5) is the most severe subtype of arrhythmogenic cardiomyopathy, caused by a point mutation in TMEM43 (p.S358L). Pathologically, the disease is characterised by dilation of the cardiac chambers and fibro-fatty replacement of the myocardium, which results in heart failure and sudden cardiac death. The function of TMEM43 and the molecular mechanism underlying ACM5 are very poorly understood, precluding the development of effective therapeutic options.
We have previously observed the interaction between the wild-type (WT) and pS358L forms of TMEM43, suggesting that WT-TMEM43 could quench the detrimental effects of the mutant protein by forming a heterodimer. Therefore, we propose that the overexpression of WT-TMEM43 could be beneficial for ACM5 progression.
Methods and results
Using our transgenic mouse models overexpressing either WT- or pS358L-TMEM43, we have generated a double transgenic mouse overexpressing both forms of the protein. The functional effects were analysed by echocardiography and electrocardiography at 5, 16 and 24 weeks of age. The lifespan of double transgenic (DT) mice increased by 10 weeks compared to mice overexpressing the mutant TMEM43 (p<0.0001). Echocardiography results show an improved systolic function of both ventricles, as observed by an increased left ventricular ejection fraction (LVEF, p<0.001) and tricuspid annular plane systolic excursion (TAPSE, p<0.01), which is already evident at 16 weeks of age. This is accompanied by an improvement in cardiac conduction, with a reduced p wave duration (p<0.001) and QRS duration (p<0.001) and increased QRS amplitude (p<0.0001) in DT mice compared to the mutant mice. In addition, histological analysis of heart samples shows a reduced fibrotic content in the myocardium of DT mice at 24 weeks of age (p<0.0001). Furthermore, the delayed raise in serum cardiac troponin I levels suggests cardiomyocyte necrosis is also delayed in the therapeutic mouse model.
Conclusion
Overall, this data provides evidence that an overexpression of WT-TMEM43 delays the onset of ACM5 phenotype and could potentially be a novel therapeutic approach for ACM5.
Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Spanish Ministry of Science and Innovation
Collapse
Affiliation(s)
- L Lalaguna
- Spanish National Centre for Cardiovascular Research , Madrid , Spain
| | - M Lopez-Olaneta
- Spanish National Centre for Cardiovascular Research , Madrid , Spain
| | | | - A Rey-Martin
- Spanish National Centre for Cardiovascular Research , Madrid , Spain
| | - P Garcia-Pavia
- Puerta de Hierro Majadahonda University Hospital, Heart Failure and Inherited Cardiac Diseases Unit, Department of Cardiology, Majadahonda , Madrid , Spain
| | - E Lara-Pezzi
- Spanish National Centre for Cardiovascular Research , Madrid , Spain
| |
Collapse
|
4
|
Frutos Seminario F, Ochoa JP, Navarro-Penalver M, Baas A, Bjerre JV, Zorio E, Mendez I, Lorca R, Verdonschot JAJ, Garcia-Granja PE, Bilinska Z, Fatkin D, Fuentes-Canamero ME, Garcia-Pinilla JM, Garcia-Pavia P. Natural history of MYH7-related dilated cardiomyopathy. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Variants in MYH7 are responsible for disease in 1–5% of patients with dilated cardiomyopathy (DCM); however, the clinical characteristics and natural history of MYH7-related DCM are poorly described.
Objectives
We sought to determine the phenotype and prognosis of MYH7-related DCM. We also evaluated the influence of variant location on phenotypic expression.
Methods
We studied clinical data from 147 individuals with DCM-causing MYH7 variants (47.6% females, 35.6±19.2 years) recruited from 29 international centers.
Results
At initial evaluation, 106 patients (72.1%) had DCM (LVEF 34.5±11.7%). Median follow-up was 4.5 years (interquartile range: 1.7–8.0). 23.7% carriers who were initially phenotype-negative developed DCM. Disease penetrance by 40 and 60 years was 46% and 88%, respectively, with 18 patients (16%) first diagnosed at <18 years. Thirty-six percent of patients with DCM met imaging criteria for LV non-compaction. During follow-up, 28% showed left ventricular reverse remodeling (LVRR). Overall incidence of end-stage heart failure (heart transplantation or heart failure related death) was 11.6% at 5 years. Overall major ventricular arrhythmia rate was low (1.0% at 5 years) even among patients with LVEF ≤35% (2.1% at 5 years). LV non-compaction was more prevalent in patients with variants in head domain (S1) (44.2%) compared with other domains (P<0.001). No differences among domain groups were found regarding LVRR, major ventricular arrhythmias or end-stage heart failure.
Conclusions
MYH7-related DCM is characterized by early age of onset, high penetrance, low rate of LVRR, and frequent progression to ESHF. Heart failure complications predominate over ventricular arrhythmias, even among patients with severe systolic disfunction.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- F Frutos Seminario
- Puerta de Hierro Majadahonda University Hospital, Majadahonda , Madrid , Spain
| | - J P Ochoa
- Puerta de Hierro Majadahonda University Hospital, Majadahonda , Madrid , Spain
| | | | - A Baas
- University Medical Center Utrecht , Utrecht , The Netherlands
| | - J V Bjerre
- Aarhus University Hospital , Aarhus , Denmark
| | - E Zorio
- University Hospital La Fe , Valencia , Spain
| | - I Mendez
- Gregorio Maranon University General Hospital - Madrid Health Service , Madrid , Spain
| | - R Lorca
- Asturias Central University Hospital , Oviedo , Spain
| | - J A J Verdonschot
- Maastricht University Medical Centre (MUMC) , Maastricht , The Netherlands
| | | | - Z Bilinska
- National Institute of Cardiology , Warsaw , Poland
| | - D Fatkin
- Victor Chang Cardiac Research Institute , Sydney , Australia
| | | | | | - P Garcia-Pavia
- Puerta de Hierro Majadahonda University Hospital, Majadahonda , Madrid , Spain
| |
Collapse
|
5
|
Cannie D, Protonotarios A, Syrris P, Sengupta A, Bilinska Z, Arana Achaga X, Barriales-Villa R, Garcia-Pavia P, Gimeno J, Merlo M, Wahbi K, Fatkin D, Mogensen J, Rasmussen TB, Elliott P. Influence of sex on cardiovascular outcomes in RBM20 variant carriers. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1744] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Variants in the RBM20 gene cause dilated cardiomyopathy and may be associated with a poor prognosis.
Objectives
To determine disease penetrance, the risk of adverse events and the influence of sex on outcomes in RBM20 variant carriers.
Methods
Consecutive probands and relatives carrying pathogenic or likely pathogenic RBM20 variants were retrospectively recruited from 12 cardiomyopathy units. The primary endpoint was a composite of malignant ventricular arrhythmia (MVA) and end-stage heart failure (ESHF). MVA and ESHF endpoints were also analysed separately and males and females compared.
Results
Longitudinal follow-up data were available for 163 RBM20 variant carriers (82 male, median age 36.5 years, median follow-up 77.6 months). 10/163 had an MVA event at baseline. 30/153 without baseline MVA (19.6%) reached the primary endpoint with a trend towards worse outcomes in males (p=0.08). 16/153 (10.5%) had new MVA with no difference between males and females (p=0.92). 20/163 (12.2%) developed ESHF (17 males and 3 females; p<0.001).
By the end of follow-up, 114 patients (70%) had either left ventricular systolic dysfunction (LVSD) or had experienced MVA. 22 patients received a first diagnosis of LVSD during follow-up. Disease penetrance in individuals over 40 years of age was 78.5% by last evaluation.
Eleven patients that reached the MVA endpoint had a left ventricular ejection fraction (LVEF) available within 6 months of the event. Median [IQR] contemporary LVEF was 30% [23.75, 40%]. 5/11 patients had a contemporary LVEF >35%. 1/11 had a contemporary LVEF >45% (a female, 1st degree relative presenting with sustained ventricular tachycardia and an LVEF of 65%).
Conclusions
RBM20 variants are highly penetrant. The risk of MVA in male and female RBM20 variant carriers is similar but male sex is strongly associated with ESHF. MVA events occur in patients with LVEF >35%.
Funding Acknowledgement
Type of funding sources: Foundation. Main funding source(s): British Heart Foundation Clinical Research Training Fellowship
Collapse
Affiliation(s)
- D Cannie
- University College London & Barts Heart Centre , London , United Kingdom
| | - A Protonotarios
- University College London & Barts Heart Centre , London , United Kingdom
| | - P Syrris
- University College London , London , United Kingdom
| | - A Sengupta
- Yorkshire Heart Centre , Leeds , United Kingdom
| | - Z Bilinska
- Institute of Cardiology, Unit for Screening Studies in Inherited Cardiovascular Disease , Warsaw , Poland
| | - X Arana Achaga
- University Hospital Donostia, Heart Failure and Inherited Cardiac Diseases , Donostia , Spain
| | - R Barriales-Villa
- Universidade da Coruna, Instituto de Investigaciόn Biomédica de A Coruña (INIBIC/ CIBERCV) , A Coruna , Spain
| | - P Garcia-Pavia
- Hospital Universitario Puerta de Hierro, IDIPHISA, CIBERCV, Heart Failure and Inherited Cardiac Diseases Unit , Madrid , Spain
| | - J Gimeno
- Virgin of the Arrixaca University Clinical Hospital, Inherited Cardiac Disease Unit , Murcia , Spain
| | - M Merlo
- University of Trieste, Cardiothoracovascular Department, Azienda Sanitaria Universitaria Integrata Giuliano Isontina , Trieste , Italy
| | - K Wahbi
- Université de Paris, Institut Imagine, AP-HP, Cochin Hospital, Cardiology Department , Paris , France
| | - D Fatkin
- Victor Chang Cardiac Research Institute , Sydney , Australia
| | - J Mogensen
- Aalborg University Hospital , Aalborg , Denmark
| | | | - P Elliott
- University College London & Barts Heart Centre , London , United Kingdom
| |
Collapse
|
6
|
Casas G, Escalona R, Gonzalez Del Hoyo MI, Palomino-Doza J, Garcia-Pinilla JM, Bayes-Genis A, Ripoll-Vera T, Jimenez-Jaimez J, Villacorta E, Gimeno-Blanes JR, Zorio E, Garcia-Pavia P, Barriales-Villa R, Ferreira-Gonzalez I, Rodriguez-Palomares JF. Outcomes of patients with left ventricular noncompaction and preserved ejection fraction. Eur Heart J Cardiovasc Imaging 2022. [DOI: 10.1093/ehjci/jeab289.419] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
INTRODUCTION
Left ventricular noncompaction (LVNC) is a poorly defined entity with heterogeneous prognosis. LV ejection fraction (LVEF) is one of the main predictors of major adverse cardiovascular events (MACE). However, outcomes of LVNC patients with preserved LVEF (pEF) remain uncertain.
PURPOSE
The aim of our study was to determine the incidence and predictors of MACE in LVNC patients with pEF as well as to assess the evolution of LVEF throughout follow-up.
METHODS
We conducted a retrospective, longitudinal, multicentre cohort study. Consecutive patients with transthoracic echocardiography (TTE) and/or cardiac magnetic resonance (CMR) diagnostic criteria for LVNC and initially pEF (LVEF≥50%) were recruited. MACE were defined as a composite of heart failure (HF), ventricular arrhythmias (VA), systemic embolisms (SE) and/or all-cause mortality. Progressive systolic dysfunction was defined as an LVEF < 50% at last TTE and/or an absolute ≥10-point decrease in LVEF from first to last TTE. Lower limit of LVEF CMR values were considered 50-57% according to current recommendations. Cox-regression analysis was used for MACE and logistic regression was used for progressive systolic dysfunction (only first and last TTE were available).
RESULTS
A total of 305 patients from 12 centres were included from 2000 to 2018. Age was 38 ± 19 years and 165 (54%) were men. LVEF was 62 ± 8% and 8% had late gadolinium enhancement (LGE). During a median follow-up of 4.7 (IQR 2.1-7.4) years, MACE occurred in 40 (13%) patients with an incidence rate of 2.73 (95% CI 2.00-3.72) events per 100 person-years: 8 HF, 27 VA, 3 SE and 5 deaths. LVEF by CMR (HR 0.95, 95% CI 0.91-0.99, p = 0.0048) and hypertension (HR 2.30, 95% CI 1.08-4.89, p = 0.031) were the only variables independently associated with the endpoint. Patients with lower limit LVEF values showed an increased risk of MACE (Figure 1). LGE was not associated.
Sixty-one (21%) patients experienced progressive systolic dysfunction: 31 (11%) had an LVEF < 50% and 48 (17%) an absolute ≥10-point decrease in LVEF at last follow-up. On multivariate analysis, LVEF by CMR was the only independent predictor (OR 0.93, 95% CI 0.89-0.98, p = 0.008). Patients with lower limit LVEF values had an increased risk (Figure 2). In this subgroup, LGE was also associated with the endpoint (HR 10.69, 95% CI 1.97-58.13, p = 0.006).
CONCLUSIONS
Patients with left ventricular noncompaction and preserved ejection fraction carry a moderate risk of major adverse cardiovascular events and progressive systolic dysfunction. LVEF remains the main predictor of outcomes in this subgroup. Patients with lower limit LVEF values are at increased risk, probably suggesting subclinical systolic dysfunction. Therefore, they should be carefully monitored. Abstract Figure. Kaplan Meier cuves for MACE Abstract Figure. Risk of progressive systolic dysfunction
Collapse
Affiliation(s)
- G Casas
- University Hospital Vall d"Hebron, Cardiology, Barcelona, Spain
| | - R Escalona
- University Hospital Vall d"Hebron, Cardiology, Barcelona, Spain
| | | | | | | | | | | | | | - E Villacorta
- Complejo Asistencial Universitario de Salamanca, Salamanca, Spain
| | - JR Gimeno-Blanes
- Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain
| | - E Zorio
- Hospital Universitario y Politecnico La Fe, Valencia, Spain
| | - P Garcia-Pavia
- University Hospital Puerta de Hierro Majadahonda, Madrid, Spain
| | | | | | | |
Collapse
|
7
|
Jimenez-Perez G, Loncaric F, Marti Castellote PM, Ramos Jovani M, Gonzales Lopez E, Gonzales Mirelis J, Piella G, Camara O, Garcia-Alvarez A, Garcia-Pavia P, Sitges M, Bijnens B. Machine learning-based phenotyping and risk assessment of hypertrophic cardiomyopathy - linking ECGs, morphology and genotypes. Eur Heart J Cardiovasc Imaging 2022. [DOI: 10.1093/ehjci/jeab289.431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
Integrating clinical data to distinguish hypertrophic cardiomyopathy (HCM) phenotypes is relevant in clinical practice. Machine learning (ML) can help - deep learning (DL) networks can automate detection and segmentation of 12-lead electrocardiograms (ECGs), whereas unsupervised learning can group patients to compare ECG, imaging and genetic characteristics. The aim is to automate ECG morphology analysis from all 12 ECG leads and multiple beats, and relate this to HCM genotypes and imaging phenotypes.
Methods
The single-center cohort included phenotype- and genotype-positive (G+) HCM patients (n = 104) and their phenotype-negative relatives (n = 50, 42% G+). All patients had a digital 12-lead ECG, echocardiography, and a magnetic resonance (CMR) study performed. The workflow is shown in Fig 1. A U-Net DL network was used for ECG delineation (P, QRS, T onsets/offsets) for all cardiac cycles. Three heartbeats were selected for each patient based on their morphology, with the aim of capturing beat-to-beat variability. An unsupervised representation learning algorithm was used to fuse ECG data and assess inter-patient similarities. Patients were clustered based on similarities of ECG biomarkers, and compared with regards to genotypes, family history of sudden cardiac death (SCD), history of ventricular arrhythmias/syncope/aborted SCD, implanted defibrillators (ICD), left ventricular (LV) obstruction, maximal wall thickness, late gadolinium enhancement (LGE), and HCM risk-SCD score.
Results
ML based on ECG biomarkers provided a good separation of HCM patients and relatives (Fig 1A), also showing G- and patients with variants of uncertain significance grouping together (Fig 1B). Clustering resulted in 6 ECG phenogroups (C1-6). C1 and 2 were related to less comorbidities, cardiac remodeling, and HCM risk score, capturing the majority of G- patients. C3 and 4 were related to LV obstruction – where C4 consisted of symptomatic patients with high ICD implantation and event rates, high LGE, and impaired systolic function. C5 captured patients with high comorbidities, extremely remodeled hearts, but no obstruction, whereas C6 patients with positive family history and high arrhythmic events (Fig 1C, Table 1). The average ECG morphology is shown side-by-side for C1 and C5 in Fig 1D – negative T waves, increased R/S wave amplitudes, left axis deviation (LAD) and ST elevation can be recognized as macro-biomarkers in C5 (yellow arrows).
Conclusion
ML can automate the analysis of complex clinical data, simultaneously taking into account the morphology of all ECG components in all 12-leads, throughout multiple beats, compare it with clinical and imaging data, and identify clinically sensible phenogroups as validated by structural and functional findings, as well as with genotypes and clinical information. Automated and comprehensive cardiac data analysis has diagnostic and research potential to help screen populations and phenotype disease etiologies. Abstract Figure 1: analysis pipeline Abstract Table 1: clinical variables
Collapse
Affiliation(s)
- G Jimenez-Perez
- Institute of Biomedical Research August Pi Sunyer (IDIBAPS), Barcelona, Spain
| | - F Loncaric
- University Hospital Centre Zagreb, Department of cardiovascular diseases, Zagreb, Croatia
| | - PM Marti Castellote
- University Pompeu Fabra, Department of Information and Communication Technologies, Barcelona, Spain
| | - M Ramos Jovani
- Hospital Clinic de Barcelona, Cardiovascular Institute, Barcelona, Spain
| | - E Gonzales Lopez
- University Hospital Puerta de Hierro Majadahonda, Department of Cardiology, Madrid, Spain
| | - J Gonzales Mirelis
- University Hospital Puerta de Hierro Majadahonda, Department of Cardiology, Madrid, Spain
| | - G Piella
- University Pompeu Fabra, Department of Information and Communication Technologies, Barcelona, Spain
| | - O Camara
- University Pompeu Fabra, Department of Information and Communication Technologies, Barcelona, Spain
| | - A Garcia-Alvarez
- Hospital Clinic de Barcelona, Cardiovascular Institute, Barcelona, Spain
| | - P Garcia-Pavia
- University Hospital Puerta de Hierro Majadahonda, Department of Cardiology, Madrid, Spain
| | - M Sitges
- Hospital Clinic de Barcelona, Cardiovascular Institute, Barcelona, Spain
| | - B Bijnens
- Catalan Institute of Research and Advanced Studies (ICREA), Barcelona, Spain
| |
Collapse
|
8
|
Abstract
Abstract
Background
Myocardial fibrosis is a common feature of hypertrophic cardiomyopathy (HCM) but its pathophysiology has yet to be elucidated.
Purpose
In this study, we used a multiplex approach to examine the genetic regulation of pathways associated with fibrosis in patients undergoing septal myectomy.
Methods
Myocardial tissue was collected at time of surgical intervention. Control biopsy samples were obtained from the left ventricular free wall from structurally normal hearts during autopsy following non-cardiac related death. Tissue was either snap frozen in liquid nitrogen and subsequently stored at −80 degrees or collected in RNA laterTM and frozen 24 hours later at −80 degrees. Total RNA was extracted from HCM tissue samples using the Qiagen RNeasy fibrous tissues mini kit and from control samples using mirVana isolation kit (Ambion), according to the manufacturer's protocol. Quantitative PCR (qPCR) was performed on the extracted RNA using a RT. Profiler™ Human finrosis PCR Array.
Results
The study cohort comprised 22 HCM samples and 5 controls. The relative regulation of genes involved in myocardial fibrosis in patients with HCM compared to controls is shown in figure 1.
In patients with HCM, there was increased expression of genes involved in collagen synthesis. A significant two-fold upregulation in type III procollagen mRNA was observed relative to controls (p=0.013) with a similar trend identified for type I procollagen (1.5 fold up-regulation, p=0.081). The gene expression of MMP3 (−1.5 fold, p=0.029) and MMP8 (−1.8, p=0.002) which are involved in collaged degradation were downregulated in the HCM group.
The gene expression of pro-fibrotic mediators TGF-β2 (4.8 fold, p=0.008) and CCN2 (2.9 fold, p=0.021) was also significantly elevated. Within the HCM group, there was a correlation between the fold regulation of TGF-β1 (r=0.570, p=0.006; r=0.528, p=0.012), TGF-β2 (r=0.569, p=0.006; r=0.514, p=0.014) and TGF-β3 (r=0.738, p<0.001; r=0.496, p=0.019) to gene regulation of type I and III procollagens respectively.
The expression of BMP-7 which has been shown to reduce myocardial fibrosis by antagonising TGF- β mediated endothelial – mesothelial transformation of fibroblasts was also down-regulated in HCM (−3.8, p=0.015).
Conclusions
Genetic expression of procollagen is significantly upregulated in patients with HCM relative to controls. TGF-β and CCN2 mediated signalling appear to be key mediators in promoting collagen expression.
Funding Acknowledgement
Type of funding sources: Other. Main funding source(s): Heart Hospital Charitable Grant, UK Figure 1. Gene expression in HCM
Collapse
Affiliation(s)
- V Patel
- University College of London, London, United Kingdom
| | - P Syrris
- University College of London, Centre for Heart Muscle Disease, Institute of Cardiovascular Science, London, United Kingdom
| | - C Coats
- University College of London, London, United Kingdom
| | - J Lucena
- Institute of Legal Medicine and Forensic Sciences of Seville, Seville, Spain
| | - E Lara-Pezzi
- University Hospital Puerta de Hierro Majadahonda, Madrid, Spain
| | - P Garcia-Pavia
- University Hospital Puerta de Hierro Majadahonda, Madrid, Spain
| | - P M Elliott
- University College of London, London, United Kingdom
| |
Collapse
|
9
|
Casas G, Limeres J, Gutierrez-Garcia L, La Mura L, Guala A, Teixido G, Escalona R, Gonzalez-Del-Hoyo M, Gimeno JR, Zorio E, Garcia-Pavia P, Barriales R, Evangelista A, Ferreira-Gonzalez I, Rodriguez-Palomares JF. Prognosis of left ventricular noncompaction with preserved ejection fraction. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1758] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
Left ventricular noncompaction (LVNC) is a poorly defined entity with heterogeneous prognosis. LV ejection fraction (LVEF) is one of the main predictors of major adverse cardiovascular events (MACE). However, outcomes of LVNC patients with preserved LVEF (pEF) remain uncertain.
Purpose
The aim of our study was to determine the incidence and predictors of MACE in LVNC patients with pEF as well as to assess the evolution of LVEF throughout follow-up.
Methods
We conducted a retrospective, longitudinal, multicentre cohort study. Consecutive patients with transthoracic echocardiography (TTE) and/or cardiac magnetic resonance (CMR) diagnostic criteria for LVNC and initially pEF (LVEF≥50%) were recruited. MACE were defined as a composite of heart failure (HF), ventricular arrhythmias (VA), systemic embolisms (SE) and/or all-cause mortality. Progressive systolic dysfunction was defined as an LVEF<50% at last TTE and/or an absolute ≥10-point decrease in LVEF from first to last TTE. Lower limit of LVEF values were considered 50–53% for TTE and 50–57% for CMR, according to current recommendations.
Results
A total of 305 patients from 12 centres were included from 2000 to 2018. Age was 38±19 years, 165 (54%) were men and 185 (61%) were probands. LVEF was 62±8% and 8% had late gadolinium enhancement (LGE). During a median follow-up of 4.7 (IQR 2.1–7.4) years, MACE occurred in 40 (13%) patients with an incidence rate of 2.96 (95% CI 2.17–4.04) events per 100 person-years: 8 HF, 27 VA, 3 SE and 5 deaths. LVEF by TTE (HR 0.95, 95% CI 0.90–0.99, p=0.035) and age (HR 1.02, 95% CI 1.01–1-04, p=0.04) were the only variables independently associated with the endpoint. Patients with lower limit LVEF values showed an increased risk of MACE (Figure 1). Among probands, those with family aggregation presented a higher incidence of MACE compared to nonfamilial cases (HR 2.74, p=0.043). A positive genotype was not associated.
Sixty-one (21%) patients experienced progressive systolic dysfunction: 31 (11%) had an LVEF<50% and 48 (17%) an absolute ≥10-point decrease in LVEF at last follow-up. On multivariate analysis, LVEF by CMR was the only independent predictor (HR 0.96, 95% CI 0.92–0.99, p=0.031). Patients with lower limit LVEF values had an increased risk (Figure 2). In this subgroup, LGE was also associated with the endpoint (HR 3.52, p=0.011). Family aggregation was not associated, while a positive genotype correlated with lower risk (HR 0.52, p=0.029).
Conclusions
Patients with left ventricular noncompaction and preserved ejection fraction carry a moderate risk of major adverse cardiovascular events and progressive systolic dysfunction. LVEF remains the main predictor of outcomes in this subgroup. Patients with lower limit LVEF values are at increased risk, probably suggesting subclinical systolic dysfunction. Therefore, they should be carefully monitored.
Funding Acknowledgement
Type of funding sources: None. Figure 1Figure 2
Collapse
Affiliation(s)
- G Casas
- University Hospital Vall d'Hebron, Cardiology, Barcelona, Spain
| | - J Limeres
- University Hospital Vall d'Hebron, Cardiology, Barcelona, Spain
| | | | - L La Mura
- Federico II University Hospital, Naples, Italy
| | - A Guala
- University Hospital Vall d'Hebron, Cardiology, Barcelona, Spain
| | - G Teixido
- University Hospital Vall d'Hebron, Cardiology, Barcelona, Spain
| | - R Escalona
- University Hospital Vall d'Hebron, Cardiology, Barcelona, Spain
| | | | - J R Gimeno
- Hospital Universitario Virgen Arrixaca, Murcia, Spain
| | - E Zorio
- Hospital Universitario y Politecnico La Fe, Valencia, Spain
| | - P Garcia-Pavia
- University Hospital Puerta de Hierro Majadahonda, Madrid, Spain
| | - R Barriales
- University Hospital Complex A Coruña, A Coruña, Spain
| | - A Evangelista
- University Hospital Vall d'Hebron, Cardiology, Barcelona, Spain
| | | | | |
Collapse
|
10
|
Rocha Lopes L, Hernandez SG, Lorenzini M, Futema M, Chumakova O, Villacorta E, Garcia-Pavia P, Bilbao R, Sandin-Fuentes M, Pinilla JG, Rasmussen TB, Revilla-Marti P, Elliott D, Monserrat L, Elliott P. Alpha-protein kinase 3 (ALPK3) truncating variants cause an autosomal dominant form of hypertrophic cardiomyopathy. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1781] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
More than half of hypertrophic cardiomyopathy (HCM) remains genetically unsolved. ALPK3 truncating variants (ALPK3tv) have been described as a cause of autosomal recessive cardiomyopathy in a small number of paediatric cases, but the pathogenicity in heterozygosity as a possible cause of autosomal dominant HCM is unknown.
Aims
To determine the frequency of heterozygous ALPK3tv in patients with HCM and to confirm their pathogenicity by means of burden testing in independent cohorts, family co-segregation studies, and functional analysis of an allelic series of ALPK3tv using human embryonic stem cell-cardiomyocytes (hESC-CM). Phenotype was compared with a cohort of 1679 genotyped HCM patients.
Methods and results
In a discovery cohort of 770 index patients with HCM, 12 (1.56%) were heterozygous for ALPK3tv, odds ratio (OR) 16.01 (95% confidence interval (95% CI): 7.89 to 29.74, p<8.36e-11), compared to the Genome Aggregation Database (gnomAD) population. In a validation cohort of 2047 HCM probands, 32 (1.56%) carried heterozygous ALPK3tv, OR 16.17 (95% CI: 10.31 to 24.87; p<2.2e-16, compared to gnomAD). Combined logarithm of odds score in 7 families with ALPK3tv was 2.99. In comparison with a large cohort of genotyped HCM patients, the phenotype of 51 HCM patients with ALPK3tv (probands and relatives) was characterised by a higher prevalence of apical/concentric patterns of hypertrophy (60%) compared to both sarcomere-positives or negatives (p<0.001 overall), with the age at diagnosis (56±16ys) and maximum wall thickness (18±4mm) similar to sarcomere-negatives and LV systolic impairment at baseline (6%) and non-sustained ventricular tachycardia (31%) similar to sarcomere-positives. Short PR (10%, p=0.009 overall) and extensive fibrosis>15% of LV segments (49%) were distinctive features. During follow-up (5.3±5.7 years), 4 (9%) patients died of heart failure or had cardiac transplantation (p=0.012 vs sarcomere-negatives and p=0.425 vs sarcomere-positives). Analysis of hESC-CM showed that ALPK3 heterozygotes had phenotypic characteristics of HCM, including increased contractile force and delayed membrane repolarization.
Conclusions
Heterozygous ALPK3tv are pathogenic and segregate with a characteristic HCM phenotype.
Funding Acknowledgement
Type of funding sources: Public Institution(s). Main funding source(s): MRC UK, UCLH BRC
Collapse
Affiliation(s)
| | - S G Hernandez
- Institute of Biomedical Research of La Coruna (INIBIC), Health In Code, A Coruna, Spain
| | - M Lorenzini
- St Bartholomew's Hospital, London, United Kingdom
| | - M Futema
- University College London, London, United Kingdom
| | - O Chumakova
- City Clinical Hospital No. 17, Moscow, Russian Federation
| | | | - P Garcia-Pavia
- University Hospital Puerta de Hierro Majadahonda, Madrid, Spain
| | - R Bilbao
- Alvaro Cunqueiro Hospital, Vigo, Spain
| | | | - J G Pinilla
- University Hospital Virgen de la Victoria, Malaga, Spain
| | | | | | - D Elliott
- University of Melbourne, Melbourne, Australia
| | - L Monserrat
- Institute of Biomedical Research of La Coruna (INIBIC), Health In Code, A Coruna, Spain
| | - P Elliott
- St Bartholomew's Hospital, London, United Kingdom
| | | |
Collapse
|
11
|
Garcia-Pavia P, Fine N, Weissman N, Castano A, Gundapaneni B, Sultan M, Shah S. Patients with transthyretin amyloid cardiomyopathy may have preserved, mildly reduced, or reduced ejection fraction. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.0717] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an often-overlooked form of heart failure with preserved ejection fraction (HFpEF). Previous studies have demonstrated that relatively high proportions of older patients with HFpEF have underlying ATTR-CM. However, while ATTR-CM should not be overlooked as a cause of HFpEF, it also should not be assumed that all patients with ATTR-CM present with HFpEF.
Purpose
To categorise patients with ATTR-CM from a large clinical trial by left ventricular ejection fraction (LVEF) at enrolment in order to describe the prevalence of HFpEF, HF with mildly reduced EF (HFmrEF), and HF with reduced EF (HFrEF).
Methods
The Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) enrolled 441 patients with ATTR-CM, including both hereditary (ATTRv) and wild-type (ATTRwt) patients. In ATTR-ACT, all patients underwent echocardiography at enrolment using a standardised protocol, and all images were reviewed and analysed at an independent central laboratory. In this analysis of patient data at enrolment, all patients in ATTR-ACT were categorised by LVEF as: HFpEF (LVEF ≥50%), HFmrEF (LVEF 41–49%), or HFrEF (LVEF ≤40%). The proportions of patients in these LVEF categories in the sub-groups of race, sex, genotype, and disease severity (by NYHA class) were assessed, together with myocardial contraction fraction (MCF) in each category.
Results
In ATTR-ACT, there were 220 (50.5%) patients with HFpEF, 119 (27.3%) with HFmrEF, and 97 (22.3%) with HFrEF (Table). Five subjects with missing LVEF at enrolment were not categorized. Asian patients had the highest proportion with HFpEF, followed by White, then Black patients. The ATTRwt group had a higher proportion of patients with HFpEF than the ATTRv group. There were significant differences (as assessed by Chi-square test; P=0.0001) in the proportion of patients in each EF category between NYHA class I or II and NYHA class III patients. Median MCF was higher in NYHA class I/II (16.6%) than NYHA class III (14.8%) patients, and higher in patients with HFpEF compared with HFmrEF and HFrEF.
Conclusions
Not all patients with ATTR-CM have HFpEF. In this analysis of patients at enrolment in ATTR-ACT half had mildly reduced or reduced LVEF, with even higher proportions of reduced EF observed in Black patients, ATTRv patients, and patients with worse functional class (NYHA class III). These data demonstrate that ATTR-CM should be considered as a possible diagnosis in all patients with HF regardless of EF.
Funding Acknowledgement
Type of funding sources: Private company. Main funding source(s): Pfizer Table 1
Collapse
Affiliation(s)
- P Garcia-Pavia
- University Hospital Puerta de Hierro Majadahonda, Madrid, Spain
| | - N Fine
- University of Calgary, Calgary, Canada
| | - N.J Weissman
- Georgetown University, Washington, DC, United States of America
| | - A Castano
- Pfizer Inc, New York, United States of America
| | | | - M.B Sultan
- Pfizer Inc, New York, United States of America
| | - S.J Shah
- Northwestern University, Chicago, United States of America
| |
Collapse
|
12
|
Casas G, Limeres J, Barriales-Villa R, Garcia-Pavia P, Zorio E, Gimeno-Blanes JR, Palomino-Doza J, Garcia-Pinilla JM, Bayes-Genis A, Ripoll-Vera T, Jimenez-Jaimez J, Villacorta E, Evangelista A, Ferreira-Gonzales I, Rodriguez-Palomares JF. Prognostic role of cardiac magnetic resonance in left ventricular noncompaction. Eur Heart J Cardiovasc Imaging 2021. [DOI: 10.1093/ehjci/jeab090.111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
Left ventricular noncompaction (LVNC) is a heterogeneous entity with a wide phenotypic expression. Risk factors have not been well established and prognostic stratification remains challenging.
Purpose
Describe prognostic role of CMR on long term outcomes of LVNC patients.
Methods
Retrospective multicentric longitudinal cohort study of consecutive patients fulfilling imaging diagnostic criteria for LVNC (Jenni echo criteria and Petersen and Jacquier CMR criteria). Demographic, ECG, genetic, family and treatment variables were recorded. Baseline CMR was used for the analysis. LV ejection fraction (LVEF) was categorized according to heart failure (HF) guidelines and late gadolinium enhancement (LGE) was visually assessed in a binary way. End points were HF, ventricular arrhythmias (VA), systemic embolisms (SE) and all-cause death. Major adverse cardiovascular events (MACE) were the combination of the four previous end points. In patients with initially preserved LVEF (≥ 50%), LV adverse remodelling (LVAR) was defined as an LVEF < 50% and/or absolute decrease of ≥10% in LVEF at last follow-up.
Results
585 patients from 12 referral centres were included from 2000 to 2018. Age at diagnosis was 45 ± 20 years, 334 (57%) were male, baseline LVEF was 48 ± 17% and 18% presented LGE. During a median follow-up of 5.1 years (IQR 2.3-8.1), 110 (19%) patients presented HF, 87 (15%) VA, 18 (3%) SE and 34 (6%) died. MACE occurred in 223 (38%) patients.
LVEF was independently associated with HF, VA, SE and MACE: HR were 1.08, 1.02, 1.04 and 1.02 respectively (all p < 0.05). LGE was more frequent in patients with reduced LVEF (39 Vs 53%, p < 0.001) and was associated with higher HF and VA risk in patients with an LVEF > 35% (HR 2.69 and 2.48 respectively, p < 0.05) (Figure 1). No MACE (0%) occurred during long-term follow-up in patients with preserved LVEF, no LGE as well as no ECG abnormalities and no family aggregation.
305 (52%) patients presented with initially preserved LVEF, and 230 (75%) of those had LVEF available at last follow-up. LVAR occurred in 50 (22%) patients: 22 (10%) had an LVEF < 50% and 41 (18%) an absolute ≥ 10% decrease in LVEF. LGE was independently associated with LVAR (HR 3.51, p = 0.045) (Figure 2).
Conclusions
Cardiac magnetic resonance has an important prognostic role in LVNC. LVEF is the most powerful predictor of events. Myocardial fibrosis is associated with worse outcomes in patients without severe systolic dysfunction, as well as with left ventricular adverse remodelling in those with initially preserved LVEF. Besides, CMR may identify a low-risk subgroup of LVNC patients. Therefore, CMR should be used in risk stratification in LVNC.
Collapse
Affiliation(s)
- G Casas
- University Hospital Vall d"Hebron, Cardiology, Barcelona, Spain
| | - J Limeres
- University Hospital Vall d"Hebron, Cardiology, Barcelona, Spain
| | | | - P Garcia-Pavia
- University Hospital Puerta de Hierro Majadahonda, Madrid, Spain
| | - E Zorio
- Hospital Universitario y Politecnico La Fe, Valencia, Spain
| | | | | | | | | | | | | | - E Villacorta
- University Hospital of Salamanca, Salamanca, Spain
| | - A Evangelista
- University Hospital Vall d"Hebron, Cardiology, Barcelona, Spain
| | | | | |
Collapse
|
13
|
Hong K, Battikha C, Lin A, John S, Brambatti M, Garcia-Alvarez A, Garcia-Guereta L, Diez C, Perez-Gomez L, Garcia-Pavia P, Taylor M, Adler E. Cardiac Transplantation in Danon Disease. J Heart Lung Transplant 2021. [DOI: 10.1016/j.healun.2021.01.781] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
14
|
Casas G, Limeres J, Oristrell G, Gutierrez L, Barriales R, Garcia-Pavia P, Zorio E, Gimeno JR, Villacorta E, Jimenez-Jaimez J, Ripoll T, Bayes A, Ferreira I, Rodriguez-Palomares JF. Long term outcomes in left ventricular noncompaction. Eur Heart J Cardiovasc Imaging 2021. [DOI: 10.1093/ehjci/jeaa356.305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
Left ventricular noncompaction (LVNC) is a heterogeneous entity with a wide phenotypic expression. Risk factors have not been well established and prognostic stratification remains challenging.
Objectives
Describe long term outcomes of LVNC patients and determine predictors of cardiovascular events.
Methods
Prospective multicentric study of consecutive patients fulfilling imaging diangostic criteria for LVNC (Jenni echo criteria and Petersen CMR criteria). Demographic, ECG, imaging and genetic variables were collected. End points were heart failure (HF), ventricular arrhythmias (VA), systemic embolisms (SE) and all-cause death. Major adverse cardiovascular events (MACE) was the combination of the four previous end points.
Results
585 patients from 12 referral centres were included from 2000 to 2018. Age at diagnosis was 45 ± 20 years, 334 (57%) were male, baseline LVEF was 48 ± 17% and 18% presented late gadolinium enhancement (LGE). During a median follow-up of 5.1 years (IQR 2.3-8.1), 110 (19%) patients presented HF, 87 (15%) VA, 18 (3%) SE and 34 (6%) died. MACE occurred in 223 (38%) patients.
LVEF was independently associated with HF, VA, SE and MACE: HR were 1.08, 1.02, 1.04 and 1.02 respectively (all p < 0.05). LGE was more frequent in patients with reduced LVEF (39 Vs 53%, p < 0.001) and was associated with higher HF and VA risk in patients with LVEF > 35% (HR 2.69 and 2.48 respectively, p < 0.05) (Figure 1). Patients with a normal ECG, LVEF≥50%, no LGE and no family aggregation presented no MACE (0%) at long term follow-up.
Among patients who underwent genetic testing (354, 61%), TTN variants and complex genotype (more than one variant) presented lower LVEF and higher HF risk. ACTC1 variants were associated with VA.
Conclusions
LVNC carries a high long term risk of heart faliure and ventricular arrhythmias. LVEF is the most important predictor and myocardial fibrosis is associated with increased risk in patients without severe systolic dysfunction. Genotype is a modifier of outcomes. These factors might be used to risk stratify LVNC patients.
Abstract Figure. Kaplan Meier survival curves
Collapse
Affiliation(s)
- G Casas
- University Hospital Vall d"Hebron, Cardiology, Barcelona, Spain
| | - J Limeres
- University Hospital Vall d"Hebron, Cardiology, Barcelona, Spain
| | - G Oristrell
- University Hospital Vall d"Hebron, Cardiology, Barcelona, Spain
| | - L Gutierrez
- University Hospital Vall d"Hebron, Cardiology, Barcelona, Spain
| | - R Barriales
- University Hospital Complex A Coru??a, A Coruna, Spain
| | - P Garcia-Pavia
- University Hospital Puerta de Hierro Majadahonda, Madrid, Spain
| | - E Zorio
- Hospital Universitario y Politecnico La Fe, Valencia, Spain
| | - JR Gimeno
- Hospital Universitario Virgen Arrixaca, Murcia, Spain
| | - E Villacorta
- Complejo Asistencial Universitario de Salamanca, Salamanca, Spain
| | | | - T Ripoll
- Hospital Son Llatzer, Palma de Mallorca, Spain
| | - A Bayes
- Germans Trias i Pujol Hospital, Badalona, Spain
| | - I Ferreira
- University Hospital Vall d"Hebron, Cardiology, Barcelona, Spain
| | | |
Collapse
|
15
|
Villalba-Orero M, Marti-Gomez-Aldaravi C, Lopez-Olaneta M, Camarero-Cadenas C, Gonzalez-Garcia M, Hernandez-Luzardo A, Martin-Torres J, Camafeita-Fernandez E, Garcia-Pavia P, Pascual-Figal D, Vazquez J, Lara-Pezzi E. Heart and lung aquaporins play a major role in severity of heart failure with preserved ejection fraction in mice and differs between comorbidities. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0852] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
Heart failure (HF) is a major public health problem worldwide. To date, HF with preserved ejection fraction (EF, HFpEF) represents half of all HF patients and its prevalence is increasing. HFpEF is associated with multiple comorbidities, including diabetes mellitus, pulmonary and systemic hypertension and obesity, mainly in elderly population. Accurately phenotyping HFpEF is crucial for the development of new therapies, appropriate patient stratification and the implementation of a personalised medicine. Cardiac and pulmonary remodelling play a major role in HFpEF severity but the specific mechanisms underlying cardiac failure and lung congestion, the last stage in HFpEF, in each comorbidity are incompletely understood, precluding the development of effective therapies. Aquaporins (AQP) are membrane proteins serving as water channels across the plasma membrane and control intra- and extracellular fluid volume and prompt to tissue oedema in many organs. However, its specific contribution in HFpEF has not been explored.
Purpose
We aimed to identify cardiac and pulmonary molecular changes associated to dysfunction and oedema in HFpEF, specific for each comorbidity.
Methods
A total of 48 C57BL/6 mice 10 weeks old were randomised to the following groups: control (Ctl; n=9), type I diabetes (Db; n=9), chronic hypoxia (PAH; n=10), obesity (Ob; n=10) and systemic arterial hypertension (SAH; n=10). Mice were followed for up to 2.5 years by echocardiography and lung ultrasound until they developed pulmonary oedema (HF) or died naturally. Lungs and heart were extracted and changes were determined by proteomic, immunohistochemistry and qRT-PCR.
Results
Diastolic dysfunction was observed in all comorbidities and above 50% of those mice developed HF. Db presented the highest ratio in developing HF. Db also showed the earliest mortality (47 weeks), whereas PAH, Ob and SAH mice survived for 82, 92 and 99 weeks, respectively (p<0.001 vs Ctl). A common finding in all groups was the development of different degrees o perivascular fibrosis. Db mice, the HFpEF severest group, showed an increase in pulmonary AQP1 and 5 (p<0.05 and p<0.001, respectively, vs Ctl). Upregulation of AQPs correlated with increased ventricular filling pressures (E/E', r2=07). Cardiac AQP4 was also markedly elevated in Db mice in left and right ventricle (p<0.001 and p=0.01, respectively, vs Ctl).
Conclusion
Increased AQPs in the lung is associated with a more aggressive development of congestion and HFpEF. In addition, increased AQP4 in the heart in the most aggressive form of HFpEF suggests a relevant role in cardiac oedema. Targeting AQPs in HFpEF may prevent oedema and decompensation.
Funding Acknowledgement
Type of funding source: Public grant(s) – National budget only. Main funding source(s): This study was supported from the Spanish Ministerio de Economía y Competitividad (RTI2018-096961-B-I00, SAF2015-65722-R and SAF2012-31451 to E.L-P. and Juan de la Cierva Incorporaciόn to M,V-O). The CNIC is supported by the Ministerio de Ciencia, Innovaciόn y Universidades (MCNU) and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505).
Collapse
Affiliation(s)
- M Villalba-Orero
- National Centre for Cardiovascular Research (CNIC), Madrid, Spain
| | | | - M Lopez-Olaneta
- National Centre for Cardiovascular Research (CNIC), Madrid, Spain
| | | | | | | | | | | | - P Garcia-Pavia
- University Hospital Puerta de Hierro Majadahonda, Madrid, Spain
| | | | - J Vazquez
- National Centre for Cardiovascular Research (CNIC), Madrid, Spain
| | - E Lara-Pezzi
- National Centre for Cardiovascular Research (CNIC), Madrid, Spain
| |
Collapse
|
16
|
Dominguez F, Lopez-Sainz A, Rocha-Lopes L, Barriales-Villa R, Climent V, Tiron C, Marques N, Rasmussen T, Espinosa M, Quarta G, Arad M, Asselbergs F, Olivotto I, Elliott P, Garcia-Pavia P. Clinical characteristics and natural history of PRKAG2 syndrome. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2086] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Purpose
Mutations in the PRKAG2 gene cause a syndrome characterized by hypertrophic cardiomyopathy, conduction disease and ventricular preexcitation. Only a small number of cases have been reported, and the natural history of the disease is poorly understood. The aim of this study is to describe phenotype and natural history of PRKAG2 mutation in a large multicenter international cohort.
Methods
We retrospectively studied clinical, electrocardiographic and echocardiographic data from 90 individuals with PRKAG2 mutations (53% males, 33±21 years) from 27 centers.
Results
At baseline evaluation, 93% of patients were in NYHA functional class I-II. Maximum left ventricular (LV) wall thickness was 18±8 mm and LV hypertrophy (LVH) was present in 60 (67%) subjects at baseline. LV ejection fraction was 61±12%. Seventeen pactients (19%) had a pacemaker (mean age at implantation 37±15and 16 (18%) had atrial fibrillation (AF) (mean age 41±23 years) and 33% had ventricular preexcitation or had undergone an accessory pathway ablation. After a median follow-up of 6 years (IQR:2.3–13.9), 71% of individuals had LVH, 29% had AF, 21% a de novo pacemaker (mean age at implantation 38±18 years), 14% required admission for heart failure (HF), 8% experienced sudden cardiac death or equivalent, 4% required a heart transplant and 13% died.
Conclusions
PRKAG2 syndrome is a severe, progressive cardiomyopathy characterized by high rates of AF, conduction disease, advanced HF and life-threatening arrhythmias. Outcome is not clearly related to the classical features of preexcitation and severe LVH, which are not always present.
Natural history of PRKAG2 syndrome
Funding Acknowledgement
Type of funding source: Public Institution(s). Main funding source(s): Instituto de Salud Carlos III (ISCIII)
Collapse
Affiliation(s)
- F Dominguez
- University Hospital Puerta de Hierro Majadahonda, Department of Cardiology, Madrid, Spain
| | - A Lopez-Sainz
- University Hospital Vall d'Hebron, Cardiology, Barcelona, Spain
| | | | | | - V Climent
- General University Hospital of Alicante, Alicante, Spain
| | - C Tiron
- University Hospital de Girona Dr. Josep Trueta, Girona, Spain
| | - N Marques
- Algarve University Hospital Center, Faro, Portugal
| | | | - M.A Espinosa
- University Hospital Gregorio Maranon, Madrid, Spain
| | - G Quarta
- Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - M Arad
- Leviev Heart Center, Sheba Medical Center and The Sackler Faculty of Medicine, Tel Aviv, Israel
| | - F Asselbergs
- University Medical Center Utrecht, Utrecht, Netherlands (The)
| | - I Olivotto
- Careggi University Hospital, Florence, Italy
| | - P Elliott
- St Bartholomew's Hospital, London, United Kingdom
| | - P Garcia-Pavia
- University Hospital Puerta de Hierro Majadahonda, Department of Cardiology, Madrid, Spain
| |
Collapse
|
17
|
Garcia Granja P, Lopez J, Ladron R, Cabezon G, Vilacosta I, Dominguez F, Olmos C, Sarria C, Lopez I, Carrasco M, Garcia-Pavia P, San Roman A. Prognostic benefit of urgent cardiac surgery in left-sided infective endocarditis. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Cardiac surgery is required in approximately 50% of patients with left-sided infective endocarditis (IE) being a high-risk procedure specially during active phase of the disease.
Purpose
To evaluate the impact of cardiac surgery in the in-hospital mortality of left-sided IE.
Methods
We used a prospective cohort of consecutive patients with definite left-sided IE between 2000 and 2017 (n=1002). A predictive model of in-hospital mortality was derived by adding the variable cardiac surgery to the already published ENDOVAL score. The benefit of cardiac surgery was calculated with the mean difference between the risk of in-hospital mortality considering urgent surgery and considering no surgery for each patient.
Results
The predictive model showed good discriminative capacity with an area under the ROC curve of 0.861 (95% CI: 0.830 - 0.891) and a good calibration (p-value in the Hosmer-Lemeshow test of 0.353). Figure shows the in-hospital mortality prediction of each patient in case of no-surgery (orange), urgent surgery (yellow) or real decision (blue). Mean reduction of in-hospital mortality risk in case of surgery for patients with a theoretical risk of in-hospital mortality between 0–20% in absence of surgery was 3.2±1.6%. For patients with a theoretical risk between 20–40% in absence of surgery the mean reduction was 8.1±1.1%. For patients with a theoretical risk between 40–60% in absence of surgery the mean reduction was 10.7±0.3%. For patients with a theoretical risk between 60–80% in absence of surgery the mean reduction was 9.7±0.9%. For patients with a theoretical risk between 80–100% in absence of surgery the mean reduction was 4.6±2.1%.
Conclusion
Urgent cardiac surgery is a protective factor of in-hospital mortality for all patients with left-sided IE but especially for those with intermediate risk.
Figure 1
Funding Acknowledgement
Type of funding source: Public Institution(s). Main funding source(s): Gerencia Regional de Salud, Junta de Castilla y Leόn
Collapse
Affiliation(s)
| | - J.A Lopez
- Institute of Heart Sciences (ICICOR), Valladolid, Spain
| | - R Ladron
- Institute of Heart Sciences (ICICOR), Valladolid, Spain
| | - G Cabezon
- Institute of Heart Sciences (ICICOR), Valladolid, Spain
| | | | - F Dominguez
- University Hospital Puerta de Hierro Majadahonda, Madrid, Spain
| | - C Olmos
- Hospital Clinic San Carlos, Madrid, Spain
| | - C Sarria
- University Hospital De La Princesa, Madrid, Spain
| | - I Lopez
- Institute of Heart Sciences (ICICOR), Valladolid, Spain
| | - M Carrasco
- Institute of Heart Sciences (ICICOR), Valladolid, Spain
| | - P Garcia-Pavia
- University Hospital Puerta de Hierro Majadahonda, Madrid, Spain
| | - A San Roman
- Institute of Heart Sciences (ICICOR), Valladolid, Spain
| |
Collapse
|
18
|
Casas G, Oristrell G, Limeres J, Gutierrez Garcia-Moreno L, Barriales R, Garcia-Pavia P, Zorio E, Gimeno J, Villacorta E, Jimenez-Jaimez J, Ripoll T, Bayes A, Diez C, Ferreira I, Rodriguez-Palomares J. Long term outcomes in left ventricular non-compaction. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Left ventricular non-compaction (LVNC) is a highly heterogeneous entity with a wide phenotypic expression. Risk factors have not been well established and prognostic stratification remains challenging.
Objectives
Describe long term outcomes of LVNC patients and determine predictors of cardiovascular events.
Methods
Prospective multicentric study of consecutive patients fulfilling imaging criteria for LVNC. Demographic, ECG, imaging and genetic variables were collected. End points were heart failure (HF), ventricular arrhythmias (VA), systemic embolisms (SE) and all-cause death. Major adverse cardiovascular event (MACE) was described as the combination of the four previous end points.
Results
592 patients from 13 referral centres were included from 2000 to 2018. Mean age at diagnosis was 45 years, 252 (43%) were female and mean LVEF was 48% (Table 1). During a median follow-up of 55 months (IQR 24–90), 144 (25%) patients presented HF, 101 (18%) VA, 27 (5%) SE and 33 (6%) died. MACE occurred in 223 (39%) patients.
In multivariate analysis, independent predictors of HF were LVEF (OR 0.9), PSAP (OR 1.17) and late gadolinium enhancement (LGE) (OR 1.3). VA were independently associated with LVEF (OR 0.97) and LGE (OR 2.51). Independent predictors of SE were LVEF (OR 0.96) and LA diameter (OR 1.07). No independent predictors of all-cause death could be described. MACE were independently associated with LVEF (OR 1.04) and PSAP (OR 1.08) (Table 1).
Among patients who underwent genetic testing (340, 57%), genotype was associated with outcomes: MYH7 and ACTC1 variants were protective while multiple mutations, TTN and MYBPC3 variants exhibited worse prognosis.
Conclusions
In a large prospective multicentric cohort of LVNC patients, there was a moderate long term incidence of cardiovascular events. LVEF and fibrosis were the main predictors and genotype was a modifier of outcomes. These factors might be used to risk stratify LVNC patients.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- G Casas
- University Hospital Vall d'Hebron, Cardiology, Barcelona, Spain
| | - G Oristrell
- University Hospital Vall d'Hebron, Cardiology, Barcelona, Spain
| | - J Limeres
- University Hospital Vall d'Hebron, Cardiology, Barcelona, Spain
| | | | - R Barriales
- University Hospital Complex A Coruña, A Coruna, Spain
| | - P Garcia-Pavia
- University Hospital Puerta de Hierro Majadahonda, Madrid, Spain
| | - E Zorio
- University Hospital y Politecnico La Fe, Valencia, Spain
| | - J.R Gimeno
- Hospital Universitario Virgen Arrixaca, Murcia, Spain
| | - E Villacorta
- Complejo Asistencial Universitario de Salamanca, Salamanca, Spain
| | | | - T Ripoll
- Hospital Son Llatzer, Palma de Mallorca, Spain
| | - A Bayes
- Germans Trias i Pujol Hospital, Badalona, Spain
| | - C Diez
- University Hospital of Bellvitge, Hospitalet De Llobregat, Spain
| | - I Ferreira
- University Hospital Vall d'Hebron, Cardiology, Barcelona, Spain
| | | |
Collapse
|
19
|
Restrepo Cordoba M, Wahbi K, Florian A, Mogensen J, Jimenez-Jaimez J, Climent-Paya V, Politano L, Garcia-Alvarez A, Arad M, Barriales-Villa R, Kubanek M, Lopes L, Jurcut R, Hazebroek M, Garcia-Pavia P. Phenotype and clinical outcomes of dystrophin associated dilated cardiomyopathy. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Mutations in dystrophin gene (DMD) can cause skeletal myopathy and dilated cardiomyopathy (DCM) independently or in combination. Natural history of DMD mutation carriers and dystrophin-associated DCM is poorly understood.
Objectives
This study sought to describe phenotype and prognosis of DMD mutations in a large multicenter cohort of Non-Duchenne DMD mutations carriers.
Methods
The study cohort comprised 223 individuals with a DMD mutation (83% males, 33±15 years at first evaluation) followed at 26 European centers. Major adverse cardiac events (MACE) were defined as a composite of cardiac death, heart transplant, LVAD implantation, aborted SCD or appropriate ICD shock.
Results
At initial evaluation, 85 patients (38%) had DCM (52 in combination with muscular disease) and 92 (41%) had isolated muscular disease. After a median follow-up of 96 months, 112 individuals (53%) had DCM and 20% of the individuals who had normal cardiac function at baseline developed DCM. DCM penetrance by age 30 was 56%. DCM onset was associated with male sex and was independent of the type of mutation, the presence of skeletal myopathy or serum creatine kinase levels. MACE occurred in 11% and 22% individuals from the entire cohort and with DCM respectively, and were more frequent in DCM patients without muscular disease than in those with skeletal myopathy (35.5% vs 17.7%; p=0.04). Among patients with DCM, 18% developed end-stage heart failure and 9% a major arrhythmic event (SCD/aborted SCD/ICD shock/VT). There were not differences in survival between patients with isolated DCM and those with DCM and muscular phenotype. Decreased LVEF and increased left ventricular end-diastolic diameter at baseline were associated with MACE. Atrial fibrillation and neurological events were also frequent. Prognosis of individuals who did not develop DCM was good with 96% survival during follow-up.
Conclusions
DCM caused by mutations in DMD is characterized by moderate penetrance but a high risk of MACE, progression to end-stage heart failure and ventricular arrythmias. DCM onset is the major determinant of prognosis in DMD mutation carriers with similar survival irrespectively of the presence of concomitant muscular disease.
Survival free of MACE analysis
Funding Acknowledgement
Type of funding source: Public grant(s) – National budget only. Main funding source(s): Instituto de Salud Carlos III. Contratos i-PFIS: Doctorados IIS-empresa en Ciencias y Tecnologías de la Salud
Collapse
Affiliation(s)
| | - K Wahbi
- Hospital Cochin, Paris, France
| | - A Florian
- University Hospital Münster, Department of Cardiology, Münster, Germany
| | - J Mogensen
- Odense University Hospital, Odense, Denmark
| | | | - V Climent-Paya
- General University Hospital of Alicante, Alicante, Spain
| | - L Politano
- University Hospital “Luigi Vanvitelli”, Napoli, Italy
| | | | - M Arad
- Sheba Medical Center, Ramat Gan, Israel
| | | | - M Kubanek
- Institute for Clinical and Experimental Medicine, Department of Cardiology, Praha, Czechia
| | - L.R Lopes
- Barts Heart Centre, London, United Kingdom
| | - R Jurcut
- Emergency Institute of Cardiovascular Diseases Prof. Dr. C.C. Iliescu, Bucharest, Romania
| | - M.R Hazebroek
- Maastricht University Medical Centre (MUMC), Maastricht, Netherlands (The)
| | - P Garcia-Pavia
- University Hospital Puerta de Hierro Majadahonda, Cardiology, Madrid, Spain
| |
Collapse
|
20
|
Garcia-Pavia P, Grogan M, Dispenzieri A, Mundayat R, Amass L, Rapezzi C. P336A descriptive analysis of patients with wild-type ATTR cardiomyopathy from the transthyretin amyloidosis outcomes survey. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz747.0170] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Transthyretin amyloidosis (ATTR amyloidosis) is a rare, life-threatening disorder caused by the deposition of amyloid fibrils composed of misfolded transthyretin (TTR). ATTR amyloidosis may arise from mutations in TTR or from aggregation of wild-type TTR (ATTRwt). ATTR amyloidosis with predominantly symptoms of cardiomyopathy (ATTR-CM) includes both hereditary and wild-type forms of the disease.
Purpose
To describe clinical history and disease presentation in a large population of patients with wild-type ATTR-CM from the Transthyretin Amyloidosis Outcomes Survey (THAOS). THAOS is an ongoing, global, longitudinal, observational survey of patients with ATTR amyloidosis, including both inherited and wild-type disease, and asymptomatic patients with TTR mutations.
Methods
Data from ATTRwt patients were extracted from THAOS (cut-off date: January 16, 2019) and demographic and clinical characteristics reported using descriptive statistics.
Results
There were 758 ATTRwt patients in THAOS (95% male). The majority of patients (69.3%) were in the United States, with the remainder in Italy (11.1%), Germany (7.3%), Spain (5.3%), and other countries (7.1%). Most patients (86.3%) were Caucasian, with 3.3% being of African Descent and 3.1% being of other races/ethnicities (7.4% missing data). The median (10–90th percentile) age at symptom onset was 69.7 (54.0–81.3) years and the median (10–90th percentile) time from symptom onset to diagnosis was 3.9 (0.1–17.8) years. Median (10–90th percentile) age at enrollment in THAOS was 76.4 (67.2–85.2) years. Nearly all subjects had either a cardiac (59.6%) or mixed cardiac and neurologic (36.5%) phenotype. At enrollment, 97.1% (577 of 594 patients assessed) had an abnormal ECG, with the prevalence of low voltage being 20.8% (115 of 552) and prevalence of left-ventricular hypertrophy being 2.1% (16 of 758). Atrial fibrillation was documented in 55% of patients (208 of 378). The mean (standard deviation [SD]) left-ventricular septum thickness was 17.5 (3.5) mm (n=505; 94.9% with thickness >12 mm) and mean (SD) left-ventricular ejection fraction (LVEF) was 48.3% (13.2) (n=511; 48.0% with LVEF <50.0%). Other signs and symptoms at enrollment were compatible with a sensory neuropathy in 54.2% of patients, autonomic neuropathy in 33.5% of patients, and motor neuropathy in 29.1% of patients. Gastrointestinal symptoms related to ATTR amyloidosis were present in 10.4% of patients.
Conclusions
Although patients with wild-type ATTR-CM tend to be older Caucasian men with a mostly cardiac disease phenotype, the clinical spectrum of ATTRwt is heterogeneous and differs from the classic phenotype. Our findings show that ATTRwt should not be considered an exclusively cardiac disease and there is a need for both cardiologic and neurologic assessment of these patients. Further study is needed to determine if the non-cardiac manifestations are due to amyloidosis or more common causes in this older population.
Acknowledgement/Funding
This study was sponsored by Pfizer.
Collapse
Affiliation(s)
- P Garcia-Pavia
- University Hospital Puerta de Hierro Majadahonda, Department of Cardiology, Madrid, Spain
| | - M Grogan
- Mayo Clinic, Department of Cardiovascular Diseases, Rochester, United States of America
| | - A Dispenzieri
- Mayo Clinic, Division of Hematology, Rochester, United States of America
| | - R Mundayat
- Pfizer Inc, New York, United States of America
| | - L Amass
- Pfizer Inc, Collegeville, United States of America
| | - C Rapezzi
- University of Bologna, Department of Experimental, Diagnostic and Specialty Medicine, Bologna, Italy
| |
Collapse
|
21
|
Akhtar M, Rangel-Sousa D, Palomino-Doza J, Arana Achaga X, Bilinska Z, Zamarreno Golvano E, Climent V, Navarro Penalver M, Barriales-Villa R, Charron P, Yotti R, Zorio E, Jimenez-Jaimez J, Garcia-Pavia P, Elliott PM. 5163Predictors of adverse cardiovascular events in patients with truncating variants in the filamin c (flnc) gene. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Truncating variants in Filamin C (FLNCtv) are associated with arrhythmogenic (AC) and dilated cardiomyopathies (DCM). Affected patients are reported to demonstrate a high incidence of arrhythmic and heart-failure related cardiovascular events. The aim of this study was to determine factors that predict adverse events in mutation carriers.
Methods
The study cohort comprised 168 FLNCtv carriers followed at 19 European centres. Baseline and longitudinal follow-up clinical data were collected. The primary endpoint was a composite of sudden cardiac death (SCD), aborted SCD, appropriate implantable cardioverter-defibrillator (ICD) shock, cardiac transplantation (HTx) and mortality from end-stage heart failure (ESHF).
Results
47 different pathogenic or likely-pathogenic FLNCtv were identified in 60 unrelated probands. In those with baseline and longitudinal data (160 patients; 57 probands), 114 (71.3%) patients exhibited evidence of cardiac disease at initial evaluation. Gene penetrance was 85% by the age of 40 years. During a median follow-up of 1.5 years (IQR 4.1), 24 individuals (15%) reached the primary endpoint – 16 arrhythmic (SCD/aborted SCD/ICD shock) and 8 heart failure (ESHF/HTx) related-events. Univariable predictors at baseline evaluation of the composite primary endpoint included proband status (HR 4.0, 95% CI: 1.5–10.9, p=0.01), symptoms of dyspnoea (HR 2.8, 95% CI: 1.2–6.4, p=0.02), LV systolic dysfunction (LVSD) (HR 12.4, 95% CI: 2.9–53.2, p=0.001), frequent ventricular ectopy (VE>500) on 24-hour Holter (HR 9.3, 95% CI: 1.2–74.7, p=0.04) and the presence of late gadolinium enhancement on CMR (HR 8.9, 95% CI: 1.2–68.5, p=0.04).
Multivariable analysis identified LVSD (LVEF <50%) at baseline as an independent predictor of the primary endpoint with a hazard ratio of 8.6 (95% CI: 1.8–41.5, p=0.007). ROC analysis using LV systolic dysfunction to predict the primary endpoint demonstrated an area under the curve of 0.84 (95% CI: 0.76–0.91, p<0.001) and identified an optimal LVEF “cut-off” of 47% for predicting adverse events with a Youden's index of 0.61 (sensitivity 0.91; specificity 0.70).
Kaplan-Meier plot to demonstrate freedom
Conclusions
LVSD is associated with an over 8-fold increase in the hazard of a primary endpoint event in FLNCtv gene carriers indicating that these patients should be considered for implantable cardioverter-defibrillator (ICD) implantation, optimal heart failure medical therapy and close clinical follow-up.
Acknowledgement/Funding
NIHR Biomedical Research Centre; Instituto de Salud Carlos III; DETECTIN-HF project; Wellcome Trust;CIBERCV; EU Regional Development Fund; FEDER.
Collapse
Affiliation(s)
- M Akhtar
- Barts Health NHS Trust, London, United Kingdom
| | | | | | - X Arana Achaga
- University Hospital Donostia, Donostia-San Sebastian, Spain
| | - Z Bilinska
- The Cardinal Stefan Wyszynski Institute of Cardiology, Warsaw, Poland
| | | | - V Climent
- General University Hospital of Alicante, Alicante, Spain
| | | | - R Barriales-Villa
- Instituto de Investigaciόn Biomédica de A Coruña (INIBIC), A Coruna, Spain
| | - P Charron
- Hospital Pitie-Salpetriere, Paris, France
| | - R Yotti
- University Hospital Gregorio Maranon, Madrid, Spain
| | - E Zorio
- Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | | | | | - P M Elliott
- University College London, London, United Kingdom
| |
Collapse
|
22
|
Casas G, Oristrell G, Limeres J, Sao-Aviles A, Barriales R, Garcia-Pavia P, Diez C, Zorio E, Villacorta E, De Antonio M, Garcia-Pinilla JM, Valverde M, Evangelista A, Ferreira-Gonzalez I, Rodriguez-Palomares JF. P5555Predictors of systemic embolisms in a large cohort of left ventricular noncompaction patients. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0499] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Left ventricular noncompaction (LVNC) is associated with an increased risk of systemic embolisms (SE). However, incidence and risk factors are not well established.
Purpose
To evaluate the rate of SE in LVNC and describe risk factors.
Methods
LNVC patients were included in a multicentric registry. Those with SE were considered for the analysis.
Results
514 patients with LVNC from 10 Spanish centres were recruited from 2000 to 2018. During a median follow-up of 4.2 years (IQR 1.9–7.1), 23 patients (4.5%) had a SE. Patients with SE (Table 1) were older at diagnosis, with no differences in gender and had similar cardiovascular risk factors. They were more frequently under oral anticoagulation (OAC). Besides, they had a more reduced LVEF, and more dilated LV and left atrium (LA). Late gadolinium enhancement (LGE) was more frequent, altogether suggesting a more severe phenotype.
Patients with SE had non-significantly higher rates of hospitalization for heart failure (33% vs 24%, p=0.31) and atrial fibrillation (35% vs 19%, p=0.10). In multivariate analysis, only LA diameter was an independent predictor of SE (OR 1.04, p=0.04). A LA diameter>45 mm had an independent 3 fold increased risk of SE (OR 3.04, p=0.02) (Image 1).
Table 1 Systemic embolisms (n=23) No systemic embolisms (n=491) p Men, n (%) 15 (65) 289 (56) 0.52 Median age at diagnosis (IQR), yr 60 (48–76) 48 (30–64) 0.02 Median follow up (IQR), yr 5.9 (3.1–7.8) 4.2 (1.8–7.1) 0.18 Hypertension, % 8 (33) 118 (24) 0.31 Diabetes mellitus, % 3 (14) 39 (8) 0.41 OAC, % 19 (83) 118 (24) 0.01 LVEF (SD), % 37 (15) 48 (17) 0.01 LVEDD (SD), mm 58 (11) 54 (10) 0.04 LVESD (SD), mm 45 (13) 38 (11) 0.01 LA diameter (SD), mm 46 (9) 39 (9) 0.01 LVEDV CMR (SD), mL 193 (75) 163 (70) 0.12 LVESV CMR (SD), mL 121 (64) 85 (64) 0.04 LGE, % 9 (40) 88 (18) 0.04
Conclusions
LVNC carries a moderate mid-term risk of SE, which appears to be irrespective of atrial fibrillation and associated with age, LV dilatation and systolic dysfunction and mainly LA dilatation. This subgroup of patients should be considered for oral anticoagulation in primary prevention.
Collapse
Affiliation(s)
- G Casas
- University Hospital Vall d'Hebron, Cardiology, CIBER-CV, Barcelona, Spain
| | - G Oristrell
- University Hospital Vall d'Hebron, Cardiology, CIBER-CV, Barcelona, Spain
| | - J Limeres
- University Hospital Vall d'Hebron, Cardiology, CIBER-CV, Barcelona, Spain
| | - A Sao-Aviles
- University Hospital Vall d'Hebron, Cardiology, CIBER-CV, Barcelona, Spain
| | - R Barriales
- University Hospital Complex A Coruña, A Coruna, Spain
| | - P Garcia-Pavia
- University Hospital Puerta de Hierro Majadahonda, Madrid, Spain
| | - C Diez
- University Hospital of Bellvitge, Barcelona, Spain
| | - E Zorio
- University Hospital La Fe, Valencia, Spain
| | - E Villacorta
- Hospital Clinico Universitario, Salamanca, Spain
| | - M De Antonio
- Germans Trias i Pujol University Hospital, Barcelona, Spain
| | | | - M Valverde
- University Hospital 12 de Octubre, Madrid, Spain
| | - A Evangelista
- University Hospital Vall d'Hebron, Cardiology, CIBER-CV, Barcelona, Spain
| | | | | |
Collapse
|
23
|
Martinez Naharro A, Kotecha T, Gonzalez-Lopez E, Corovic A, Anderson S, Chacko L, Brown J, Knight DS, Baksi AJ, Moon JC, Kellman P, Garcia-Pavia P, Gillmore J, Hawkins P, Fontana M. 549High prevalence of intracardiac thrombi in cardiac amyloidosis. Eur Heart J Cardiovasc Imaging 2019. [DOI: 10.1093/ehjci/jez125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- A Martinez Naharro
- University College London, CMR Unit at Royal Free Hospital, London, United Kingdom of Great Britain & Northern Ireland
| | - T Kotecha
- University College London, CMR Unit at Royal Free Hospital, London, United Kingdom of Great Britain & Northern Ireland
| | - E Gonzalez-Lopez
- University Hospital Puerta de Hierro Majadahonda, Department of Cardiology, Madrid, Spain
| | - A Corovic
- University College London, CMR Unit at Royal Free Hospital, London, United Kingdom of Great Britain & Northern Ireland
| | - S Anderson
- University College London, CMR Unit at Royal Free Hospital, London, United Kingdom of Great Britain & Northern Ireland
| | - L Chacko
- University College London, CMR Unit at Royal Free Hospital, London, United Kingdom of Great Britain & Northern Ireland
| | - J Brown
- University College London, CMR Unit at Royal Free Hospital, London, United Kingdom of Great Britain & Northern Ireland
| | - D S Knight
- University College London, CMR Unit at Royal Free Hospital, London, United Kingdom of Great Britain & Northern Ireland
| | - A J Baksi
- Royal Brompton Hospital, London, United Kingdom of Great Britain & Northern Ireland
| | - J C Moon
- Barts Health NHS Trust, London, United Kingdom of Great Britain & Northern Ireland
| | - P Kellman
- National Institutes of Health, National Heart, Lung and Blood Institute, Bethesda, United States of America
| | - P Garcia-Pavia
- University Hospital Puerta de Hierro Majadahonda, Department of Cardiology, Madrid, Spain
| | - J Gillmore
- University College London, CMR Unit at Royal Free Hospital, London, United Kingdom of Great Britain & Northern Ireland
| | - P Hawkins
- University College London, CMR Unit at Royal Free Hospital, London, United Kingdom of Great Britain & Northern Ireland
| | - M Fontana
- University College London, CMR Unit at Royal Free Hospital, London, United Kingdom of Great Britain & Northern Ireland
| |
Collapse
|
24
|
Dominguez Rodriguez F, Fernandez Alvira JM, Fernandez Friera L, Lopez-Melgar B, Blanco-Rojo R, Fernandez-Ortiz A, Garcia-Pavia P, Sanz JM, Mendiguren JM, Ibanez B, Bueno H, Fuster V, Lara-Pezzi E, Ordovas JM. P2466Association of actigraphy-measured sleep parameters and subclinical atherosclerotic burden: the PESA study. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p2466] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- F Dominguez Rodriguez
- University Hospital Puerta de Hierro Majadahonda, National Centre for Cardiovascular Research (CNIC). CIBERCV, Madrid, Spain
| | | | - L Fernandez Friera
- National Centre for Cardiovascular Research (CNIC), CIBERCV.HM Hospitales-Centro Integral de Enfermedades Cardiovasculares HM-CIEC, Madrid, Spain, Madrid, Spain
| | - B Lopez-Melgar
- National Centre for Cardiovascular Research (CNIC), HM Hospitales-Centro Integral de Enfermedades Cardiovasculares HM-CIEC, Madrid, Spain, Madrid, Spain
| | | | - A Fernandez-Ortiz
- National Centre for Cardiovascular Research (CNIC), CIBERCV. Universidad Complutense.Cardiovascular Institute, IDSSC, Hospital Clínico San Carlos, Madrid, Spain
| | - P Garcia-Pavia
- University Hospital Puerta de Hierro Majadahonda, CIBERCV. Faculty of Health Sciences, University Francisco de Vitoria (UFV), Madrid, Spain
| | - J M Sanz
- Mount Sinai School of Medicine, Zena and Michael A. Wiener Cardiovascular Institute. CNIC (Madrid), New York, United States of America
| | | | - B Ibanez
- National Centre for Cardiovascular Research (CNIC), CIBERCV, IIS-Fundaciόn Jiménez Díaz Hospital, Madrid, Spain
| | - H Bueno
- National Centre for Cardiovascular Research (CNIC), Cardiology Department, Hospital Universitario 12 de Octubre.Universidad Complutense de Madrid, Madrid, Spain
| | - V Fuster
- National Centre for Cardiovascular Research (CNIC), Zena and Michael A. Wiener Cardiovascular Institute. Icahn School of Medicine Mount Sinai, New York, Madrid, Spain
| | - E Lara-Pezzi
- National Centre for Cardiovascular Research (CNIC), CIBERCV, Madrid, Spain
| | - J M Ordovas
- National Centre for Cardiovascular Research (CNIC), IMDEA Food Institute, CEI UAM + CSIC,U.S. Dept of Agriculture HNRCA. Tufts University, Boston, US, Madrid, Spain
| | | |
Collapse
|
25
|
Dominguez Rodriguez F, Padron-Barthe L, Villalba-Orero M, Lopez-Olaneta M, Larrasa-Alonso J, Ortiz-Sanchez P, Bello E, Marti Gomez-Aldaravi C, Garcia-Pavia P, Lara-Pezzi E. P5710Usefulness of preventive heart failure treatment in mice with arrhythmogenic cardiomyopathy type 5. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p5710] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- F Dominguez Rodriguez
- National Centre for Cardiovascular Research (CNIC), Inherited Cardiac Disease Unit, Hospital Universitario Puerta de Hierro, Madrid. CNIC, Madrid, Spain
| | - L Padron-Barthe
- National Centre for Cardiovascular Research (CNIC), Madrid, Spain
| | - M Villalba-Orero
- National Centre for Cardiovascular Research (CNIC), Madrid, Spain
| | - M Lopez-Olaneta
- National Centre for Cardiovascular Research (CNIC), Madrid, Spain
| | - J Larrasa-Alonso
- National Centre for Cardiovascular Research (CNIC), Madrid, Spain
| | - P Ortiz-Sanchez
- National Centre for Cardiovascular Research (CNIC), Madrid, Spain
| | - E Bello
- National Centre for Cardiovascular Research (CNIC), Madrid, Spain
| | | | - P Garcia-Pavia
- University Hospital Puerta de Hierro Majadahonda, Inherited Cardiac Disease Unit. CNIC, Madrid, Spain
| | - E Lara-Pezzi
- National Centre for Cardiovascular Research (CNIC), Inherited Cardiac Disease Unit, Hospital Universitario Puerta de Hierro, Madrid. CNIC, Madrid, Spain
| |
Collapse
|
26
|
Dominguez Rodriguez F, Cuenca S, Bilinska Z, Toro R, Charron P, Barriales-Villa R, Asselbergs F, Akhtar M, Morris Hey T, Rangel-Sousa D, Limeres JM, Garcia-Pinilla JM, Ochoa JP, Elliott P, Garcia-Pavia P. P3169Clinical characteristics and natural history of dilated cardiomyopathy due to BAG3 mutations. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p3169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- F Dominguez Rodriguez
- University Hospital Puerta de Hierro Majadahonda, Inherited Cardiac Disease Unit, CNIC, CIBERCV, Madrid, Spain
| | - S Cuenca
- University Hospital Gregorio Maranon, Madrid, Spain
| | - Z Bilinska
- The Cardinal Stefan Wyszynski Institute of Cardiology, Warsaw, Poland
| | - R Toro
- University Hospital Puerta del Mar, Cadiz, Spain
| | - P Charron
- Hospital Pitie-Salpetriere, Paris, France
| | | | - F Asselbergs
- University Medical Center Utrecht, Utrecht, Netherlands
| | - M Akhtar
- St Bartholomew's Hospital, London, United Kingdom
| | | | | | - J M Limeres
- University Hospital Vall d'Hebron, Barcelona, Spain
| | - J M Garcia-Pinilla
- University Hospital Virgen de la Victoria, IBIMA, CIBERCV, Malaga, Spain
| | | | - P Elliott
- St Bartholomew's Hospital, London, United Kingdom
| | - P Garcia-Pavia
- University Hospital Puerta de Hierro Majadahonda, Inherited Cardiac Disease Unit, CNIC, CIBERCV, Madrid, Spain
| | | |
Collapse
|
27
|
Restrepo Cordoba MA, Barton PJ, Bayes-Genis A, Govind R, Serrano I, Midwinter W, Pascual-Figal D, Wilk A, Garcia Pinilla JM, Cook SA, Provencio M, Lyon A, Alonso-Pulpon L, Ware JS, Garcia-Pavia P. P1503Genetic predisposing factors in chemotherapy-induced cardiomyopathy. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p1503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | - P J Barton
- Royal Brompton Hospital, London, United Kingdom
| | - A Bayes-Genis
- Germans Trias i Pujol Hospital, Badalona (Barcelona), Spain
| | - R Govind
- Royal Brompton Hospital, London, United Kingdom
| | - I Serrano
- Hospital Universitario Joan XXIII, Tarragona, Spain
| | - W Midwinter
- Royal Brompton Hospital, London, United Kingdom
| | - D Pascual-Figal
- Hospital Clínico Univeristario Virgen de la Arrixaca, Murcia, Spain
| | - A Wilk
- Royal Brompton Hospital, London, United Kingdom
| | | | - S A Cook
- Royal Brompton Hospital, London, United Kingdom
| | - M Provencio
- University Hospital Puerta de Hierro Majadahonda, Medical Oncology Department, Madrid, Spain
| | - A Lyon
- Royal Brompton Hospital, London, United Kingdom
| | - L Alonso-Pulpon
- University Hospital Puerta de Hierro Majadahonda, Cardiology, Madrid, Spain
| | - J S Ware
- Royal Brompton Hospital, London, United Kingdom
| | - P Garcia-Pavia
- University Hospital Puerta de Hierro Majadahonda, Cardiology, Madrid, Spain
| |
Collapse
|
28
|
Dominguez Rodriguez F, Padron-Barthe L, Villalba-Orero M, Lopez-Olaneta M, Larrasa-Alonso J, Ortiz-Sanchez P, Bello-Arroyo E, Garcia-Pavia P, Lara-Pezzi E. 434Effect of preventive heart failure treatment in mice with arrhythmogenic right ventricular cardiomyopathy type 5 due to mutation in TMEM43. Cardiovasc Res 2018. [DOI: 10.1093/cvr/cvy060.303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | - L Padron-Barthe
- National Centre for Cardiovascular Research (CNIC), Madrid, Spain
| | - M Villalba-Orero
- National Centre for Cardiovascular Research (CNIC), Madrid, Spain
| | - M Lopez-Olaneta
- National Centre for Cardiovascular Research (CNIC), Madrid, Spain
| | - J Larrasa-Alonso
- National Centre for Cardiovascular Research (CNIC), Madrid, Spain
| | - P Ortiz-Sanchez
- National Centre for Cardiovascular Research (CNIC), Madrid, Spain
| | - E Bello-Arroyo
- National Centre for Cardiovascular Research (CNIC), Madrid, Spain
| | - P Garcia-Pavia
- University Hospital Puerta de Hierro Majadahonda, Department of Cardiology, Madrid, Spain
| | - E Lara-Pezzi
- National Centre for Cardiovascular Research (CNIC), Madrid, Spain
| |
Collapse
|
29
|
Amor-Salamanca A, Castillo S, Gonzalez-Vioque E, Dominguez F, Quintana L, Lluis-Gamella C, Escudier-Villa J, Ortega-Marcos J, Alonso-Pulpon L, Garcia-Pavia P. 2188Prevalence of genetically confirmed familial hypercholesterolemia in patients with acute coronary syndrome. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.2188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
30
|
Mademont-Soler I, Mates J, Campuzano O, Sarquella-Brugada G, Arbelo E, Brugada J, Garcia-Pavia P, Yotti R, Gonzalez-Hevia J, Borregan M, Trujillo F, Diaz F, Diaz De Bustamante A, Lopez Granados A, Brugada R. 3869Targeted next-generation sequencing as a comprehensive test for patients with hypertrophic cardiomyopathy. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.3869] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Larrasa-Alonso J, Villalba M, Sanchez-Cabo F, Marti-Gomez C, Ortiz-Sanchez P, Lopez-Olaneta M, Garcia-Pavia P, Lara-Pezzi E. 1981Loss of SRSF4 in cardiomyocytes induces hypertrophy, diastolic dysfunction and risk of sudden death. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.1981] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
32
|
Zegri Reiriz I, Dominguez F, De Alarcon A, Munoz P, Martinez-Selles M, Gonzalez-Ramallo V, Miro J, Falces C, Gonzalez-Rico C, Kortajarena -Urkola X, Lepe J, Rodriguez R, Reguera-Iglesias J, Navas E, Garcia-Pavia P. P4542Infective endocarditis antibiotic prophylaxis in mitral valve prolapse and bicuspid aortic valve: should it be considered? Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.p4542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- I. Zegri Reiriz
- University Hospital Puerta de Hierro Majadahonda, Department of Cardiology, Madrid, Spain
| | - F. Dominguez
- University Hospital Puerta de Hierro Majadahonda, Department of Cardiology, Madrid, Spain
| | - A. De Alarcon
- Institute of Biomedicine of Seville (IBIS), Seville, Spain
| | - P. Munoz
- University Hospital Gregorio Maranon, Department of Microbiology and Infectious Disease, Madrid, Spain
| | - M. Martinez-Selles
- University Hospital Gregorio Maranon, Department of Cardiology, Madrid, Spain
| | - V. Gonzalez-Ramallo
- University Hospital Gregorio Maranon, Department of General Medicine, Madrid, Spain
| | - J.M. Miro
- Hospital Clinic de Barcelona, Department of Cardiology, Barcelona, Spain
| | - C. Falces
- Hospital Clinic de Barcelona, Department of Cardiology, Barcelona, Spain
| | - C. Gonzalez-Rico
- University Hospital Marques de Valdecilla, Department of Infectious Disease, Santander, Spain
| | | | - J.A. Lepe
- Institute of Biomedicine of Seville (IBIS), Seville, Spain
| | - R. Rodriguez
- Hospital de Cruces, Department of Infectious Disease, Bilbao, Spain
| | - J.M. Reguera-Iglesias
- Regional University Hospital of Malaga, Department of Infectious Disease, Malaga, Spain
| | - E. Navas
- University Hospital Ramon y Cajal de Madrid, Department of Infectious Disease, Madrid, Spain
| | - P. Garcia-Pavia
- University Hospital Puerta de Hierro Majadahonda, Department of Cardiology, Madrid, Spain
| | | |
Collapse
|
33
|
Lara-Pezzi E, Padron-Barthe L, Villalba-Orero M, Gomez-Salinero J, Acin-Perez R, Lopez-Olaneta M, Bonzon- Kulichenko E, Vazquez J, Garcia-Pavia P, Enriquez JA. 2887Activation of serine-one-carbon metabolism by the calcineurin variant CnAbeta1 reduces cardiac hypertrophy and improves function. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx494.2887] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
34
|
Villalba-Orero M, Sanchez-Elexpuru G, Lopez-Olaneta M, Larrasa-Alonso J, Campuzano O, Moncayo-Arlandi J, Bello-Arroyo E, Padron-Barthe L, Garcia-Pavia P, Serratosa J, Brugada R, Sanchez M, Lara-Pezzi E. 42Mice with Lafora disease develop metabolic hypertrophic cardiomyopathy and cardiac dysfunction. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx501.42] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Gonzalez-Valdes I, Hidalgo I, Bujarrabal A, Lara-Pezzi E, Padron-Barthe L, Garcia-Pavia P, Gómez-del Arco P, Redondo JM, Ruiz-Cabello JM, Jimenez-Borreguero LJ, Enriquez JA, de la Pompa JL, Hidalgo A, Gonzalez S. Correction: Retraction: Bmi1 limits dilated cardiomyopathy and heart failure by inhibiting cardiac senescence. Nat Commun 2017; 8:14006. [PMID: 28266548 PMCID: PMC5344278 DOI: 10.1038/ncomms14006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
36
|
Andre E, Yaniz-Galende E, Hamilton C, Dusting GJ, Hellen N, Poulet CE, Diez Cunado M, Smits AM, Lowe V, Eckardt D, Du Pre B, Sanz Ruiz R, Moerkamp AT, Tribulova N, Smani T, Liskova YV, Greco S, Guzzolino E, Franco D, Lozano-Velasco E, Knorr M, Pavoine C, Bukowska A, Van Linthout S, Miteva K, Sulzgruber P, Latet SC, Portnychenko A, Cannavo A, Kamilova U, Sagach VF, Santin Y, Octavia Y, Haller PM, Octavia Y, Rubies C, Dei Zotti F, Wong KHK, Gonzalez Miqueo A, Kruithof BPT, Kadur Nagaraju C, Shaposhnikova Y, Songia P, Lindner D, Wilson C, Benzoni P, Fabbri A, Campostrini G, Jorge E, Casini S, Mengarelli I, Nikolov A, Bublikov DS, Kheloufi M, Rubies C, Walker RE, Van Dijk RA, Posthuma JJ, Dumitriu IE, Karshovska E, Sakic A, Alexandru N, Martin-Lorenzo M, Molica F, Taylor RF, Mcarthur L, Crocini C, Matsuyama TA, Mazzoni L, Lin WK, Owen TJ, Scigliano M, Sheehan A, Bezerra Gurgel AR, Bromage DI, Kiss A, Ikeda G, Pickard JMJ, Wirth G, Casos K, Khudiakov A, Nistal JF, Ferrantini C, Park SJ, Di Maggio S, Gentile F, Dini L, Buyandelger B, Larrasa-Alonso J, Schirmer I, Chin SH, Cimiotti D, Martini H, Hohensinner PJ, Garabito M, Zeni F, Licholai S, De Bortoli M, Sivitskaya L, Viczenczova C, Rainer PP, Smith LE, Suna G, Gambardella J, Cozma A, De Gonzalo Calvo D, Scoditti E, Clark BJ, Mansfield C, Eckardt D, Gomez L, Llucia-Valldeperas A, De Pauw A, Porporato P, Bouzin C, Draoui N, Sonveaux P, Balligand JL, Mougenot N, Formicola L, Nadaud S, Dierick F, Hajjar RJ, Marazzi G, Sassoon D, Hulot JS, Zamora VR, Burton FL, Macquaide N, Smith GL, Hernandez D, Sivakumaran P, Millard R, Wong RCB, Pebay A, Shepherd RK, Lim SY, Owen T, Jabbour RJ, Kloc M, Kodagoda T, Denning C, Harding SE, Ramos S, Terracciano C, Gorelik J, Wei K, Bushway P, Ruiz-Lozano P, Mercola M, Moerkamp AT, Vegh AMD, Dronkers E, Lodder K, Van Herwaarden T, Goumans MJ, Pellet-Many C, Zachary I, Noack K, Bosio A, Feyen DAM, Demkes EJ, Dierickx PJ, Doevendans PA, Vos MA, Van Veen AAB, Van Laake LW, Fernandez Santos ME, Suarez Sancho S, Fuentes Arroyo L, Plasencia Martin V, Velasco Sevillano P, Casado Plasencia A, Climent AM, Guillem M, Atienza Fernandez F, Fernandez-Aviles F, Dingenouts CKE, Lodder K, Kruithof BPT, Van Herwaarden T, Vegh AMD, Goumans MJ, Smits AM, Knezl V, Szeiffova Bacova B, Egan Benova T, Viczenczova C, Goncalvesova E, Slezak J, Calderon-Sanchez E, Diaz I, Ordonez A, Salikova SP, Zaccagnini G, Voellenkle C, Sadeghi I, Maimone B, Castelvecchio S, Gaetano C, Menicanti L, Martelli F, Hatcher C, D'aurizio R, Groth M, Baugmart M, Mercatanti A, Russo F, Mariani L, Magliaro C, Pitto L, Lozano-Velasco E, Jodar-Garcia A, Galiano-Torres J, Lopez-Navarrete I, Aranega A, Wagensteen R, Quesada A, Aranega A, Franco D, Finger S, Karbach S, Kossmann S, Muenzel T, Wenzel P, Keck M, Mougenot N, Favier S, Fuand A, Atassi F, Barbier C, Lompre AM, Hulot JS, Nikonova Y, Pluteanu F, Kockskaemper J, Chilukoti RK, Wolke C, Lendeckel U, Gardemann A, Goette A, Miteva K, Pappritz K, Mueller I, El-Shafeey M, Ringe J, Tschoepe C, Pappritz K, El-Shafeey M, Ringe J, Tschoepe C, Van Linthout S, Koller L, Richter B, Blum S, Koprak M, Huelsmann M, Pacher R, Goliasch G, Wojta J, Niessner A, Van Herck PL, Claeys MJ, Haine SE, Lenders GD, Miljoen HP, Segers VF, Vandendriescche TR, Hoymans VY, Vrints CJ, Lapikova-Bryhinska T, Gurianova V, Portnichenko H, Vasylenko M, Zapara Y, Portnichenko V, Liccardo D, Lymperopoulos A, Santangelo M, Leosco D, Koch WJ, Ferrara N, Rengo G, Alieva T, Rasulova Z, Masharipova D, Dorofeyeva NA, Drachuk KO, Sicard P, Yucel Y, Dutaur M, Vindis C, Parini A, Mialet-Perez J, Van Deel ED, De Boer M, De Waard MC, Duncker DJ, Nagel F, Inci M, Santer D, Hallstroem S, Podesser BK, Kararigas G, De Boer M, Kietadisorn R, Swinnen M, Duimel H, Verheyen F, Chrifi I, Brandt MM, Cheng C, Janssens S, Moens AL, Duncker DJ, Batlle M, Dantas AP, Sanz M, Sitges M, Mont L, Guasch E, Lobysheva I, Beauloye C, Balligand JL, Vanhoutte PM, Tang EHC, Beaumont J, Lopez B, Ravassa S, Hermida N, Valencia F, Gomez-Doblas JJ, San Jose G, De Teresa E, Diez J, Van De Merbel AF, Kruithof-De Julio M, Goumans MJ, Claus P, Dries E, Angelo Singh A, Vermeulen K, Roderick HL, Sipido KR, Driesen RB, Ilchenko I, Bobronnikova L, Myasoedova V, Alamanni F, Tremoli E, Poggio P, Becher PM, Gotzhein F, Klingel K, Blankenberg S, Westermann D, Zi M, Cartwright E, Campostrini G, Bonzanni M, Milanesi R, Bucchi A, Baruscotti M, Difrancesco D, Barbuti A, Fantini M, Wilders R, Severi S, Benzoni P, Dell' Era P, Serzanti M, Olesen MS, Muneretto C, Bisleri G, Difrancesco D, Baruscotti M, Bucchi A, Barbuti A, Amoros-Figueras G, Raga S, Campos B, Alonso-Martin C, Rodriguez-Font E, Vinolas X, Cinca J, Guerra JM, Mengarelli I, Schumacher CA, Veldkamp MW, Verkerk AO, Remme CA, Veerman C, Guan K, Stauske M, Tan H, Barc J, Wilde A, Verkerk A, Bezzina C, Tsinlikov I, Tsinlikova I, Nicoloff G, Blazhev A, Garev A, Andrienko AV, Lychev VG, Vorobova EN, Anchugina DA, Vion AC, Hammoutene A, Poisson J, Dupont N, Souyri M, Tedgui A, Codogno P, Boulanger CM, Rautou PE, Dantas AP, Batlle M, Guasch E, Torres M, Montserrat JM, Almendros I, Mont L, Austin CA, Holt CM, Rijs K, Wezel A, Hamming JF, Kolodgie FD, Virmani R, Schaapherder AF, Lindeman JHN, Posma JJN, Van Oerle R, Spronk HMH, Ten Cate H, Dinkla S, Kaski JC, Schober A, Chaabane C, Ambartsumian N, Grigorian M, Bochaton-Piallat ML, Dragan E, Andrei E, Niculescu L, Georgescu A, Gonzalez-Calero L, Maroto AS, Martinez PJ, Heredero A, Aldamiz-Echevarria G, Vivanco F, Alvarez-Llamas G, Meens MJ, Pelli G, Foglia B, Scemes E, Kwak BR, Caldwell JL, Eisner DA, Dibb KM, Trafford AW, Chilton L, Smith GL, Nicklin SA, Coppini R, Ferrantini C, Yan P, Loew LM, Poggesi C, Cerbai E, Pavone FS, Sacconi L, Tanaka H, Ishibashi-Ueda H, Takamatsu T, Coppini R, Ferrantini C, Gentile F, Pioner JM, Santini L, Sartiani L, Bargelli V, Poggesi C, Mugelli A, Cerbai E, Maciejewska M, Bolton EL, Wang Y, O'brien F, Ruas M, Lei M, Sitsapesan R, Galione A, Terrar DA, Smith JG, Garcia D, Barriales-Villa R, Monserrat L, Harding SE, Denning C, Marston SB, Watson S, Tkach S, Faggian G, Terracciano CM, Perbellini F, Eiros Zamora J, Papadaki M, Messer A, Marston S, Gould I, Johnston A, Dunne M, Smith G, Kemi OJ, Pillai M, Davidson SM, Yellon DM, Tratsiakovich Y, Jang J, Gonon AT, Pernow J, Matoba T, Koga J, Egashira K, Burke N, Davidson SM, Yellon DM, Korpisalo P, Hakkarainen H, Laidinen S, Yla-Herttuala S, Ferrer-Curriu G, Perez M, Permanyer E, Blasco-Lucas A, Gracia JM, Castro MA, Barquinero J, Galinanes M, Kostina D, Kostareva A, Malashicheva A, Merino D, Ruiz L, Gomez J, Juarez C, Gil A, Garcia R, Hurle MA, Coppini R, Pioner JM, Gentile F, Mazzoni L, Rossi A, Tesi C, Belardinelli L, Olivotto I, Cerbai E, Mugelli A, Poggesi C, Eun-Ji EJ, Lim BK, Choi DJ, Milano G, Bertolotti M, De Marchis F, Zollo F, Sommariva E, Capogrossi MC, Pompilio G, Bianchi ME, Raucci A, Pioner JM, Coppini R, Scellini B, Tardiff J, Tesi C, Poggesi C, Ferrantini C, Mazzoni L, Sartiani L, Coppini R, Diolaiuti L, Ferrari P, Cerbai E, Mugelli A, Mansfield C, Luther P, Knoell R, Villalba M, Sanchez-Cabo F, Lopez-Olaneta MM, Ortiz-Sanchez P, Garcia-Pavia P, Lara-Pezzi E, Klauke B, Gerdes D, Schulz U, Gummert J, Milting H, Wake E, Kocsis-Fodor G, Brack KE, Ng GA, Kostareva A, Smolina N, Majchrzak M, Moehner D, Wies A, Milting H, Stehle R, Pfitzer G, Muegge A, Jaquet K, Maggiorani D, Lefevre L, Dutaur M, Mialet-Perez J, Parini A, Cussac D, Douin-Echinard V, Ebenbauer B, Kaun C, Prager M, Wojta J, Rega-Kaun G, Costa G, Onetti Y, Jimenez-Altayo F, Vila E, Dantas AP, Milano G, Bertolotti M, Scopece A, Piacentini L, Bianchi ME, Capogrossi MC, Pompilio G, Colombo G, Raucci A, Blaz M, Kapelak B, Sanak M, Bauce B, Calore C, Lorenzon A, Calore M, Poloni G, Mazzotti E, Rigato I, Daliento L, Basso C, Thiene G, Melacini P, Corrado D, Rampazzo A, Danilenko NG, Vaikhanskaya TG, Davydenko OG, Szeiffova Bacova B, Kura B, Egan Benova T, Yin CH, Kukreja R, Slezak J, Tribulova N, Lee DI, Sorge M, Glabe C, Paolocci N, Guarnieri C, Tomaselli GF, Kass DA, Van Eyk JE, Agnetti G, Cordwell SJ, White MY, Wojakowski W, Lynch M, Barallobre-Barreiro J, Yin X, Mayr U, White S, Jahingiri M, Hill J, Mayr M, Sorriento D, Ciccarelli M, Fiordelisi A, Campiglia P, Trimarco B, Iaccarino G, Sitar Taut AV, Schiau S, Orasan O, Halloumi W, Negrean V, Zdrenghea D, Pop D, Van Der Meer RW, Rijzewijk LJ, Smit JWA, Revuelta-Lopez E, Nasarre L, Escola-Gil JC, Lamb HJ, Llorente-Cortes V, Pellegrino M, Massaro M, Carluccio MA, Calabriso N, Wabitsch M, Storelli C, De Caterina R, Church SJ, Callagy S, Begley P, Kureishy N, Mcharg S, Bishop PN, Unwin RD, Cooper GJS, Mawad D, Perbellini F, Tonkin J, Bello SO, Simonotto JD, Lyon AR, Stevens MM, Terracciano CM, Harding SE, Kernbach M, Czichowski V, Bosio A, Fuentes L, Hernandez-Redondo I, Guillem MS, Fernandez ME, Sanz R, Atienza F, Climent AM, Fernandez-Aviles F, Soler-Botija C, Prat-Vidal C, Galvez-Monton C, Roura S, Perea-Gil I, Bragos R, Bayes-Genis A. Poster session 1Cell growth, differentiation and stem cells - Heart72Understanding the metabolism of cardiac progenitor cells: a first step towards controlling their proliferation and differentiation?73Expression of pw1/peg3 identifies a new cardiac adult stem cell population involved in post-myocardial infarction remodeling74Long-term stimulation of iPS-derived cardiomyocytes using optogenetic techniques to promote phenotypic changes in E-C coupling75Benefits of electrical stimulation on differentiation and maturation of cardiomyocytes from human induced pluripotent stem cells76Constitutive beta-adrenoceptor-mediated cAMP production controls spontaneous automaticity of human induced pluripotent stem cell-derived cardiomyocytes77Formation and stability of T-tubules in cardiomyocytes78Identification of miRNAs promoting human cardiomyocyte proliferation by regulating Hippo pathway79A direct comparison of foetal to adult epicardial cell activation reveals distinct differences relevant for the post-injury response80Role of neuropilins in zebrafish heart regeneration81Highly efficient immunomagnetic purification of cardiomyocytes derived from human pluripotent stem cells82Cardiac progenitor cells posses a molecular circadian clock and display large 24-hour oscillations in proliferation and stress tolerance83Influence of sirolimus and everolimus on bone marrow-derived mesenchymal stem cell biology84Endoglin is important for epicardial behaviour following cardiac injuryCell death and apoptosis - Heart87Ultrastructural alterations reflecting Ca2+ handling and cell-to-cell coupling disorders precede occurrence of severe arrhythmias in intact animal heart88Urocortin-1 promotes cardioprotection through ERK1/2 and EPAC pathways: role in apoptosis and necrosis89Expression p38 MAPK and Cas-3 in myocardium LV of rats with experimental heart failure at melatonin and enalapril introductionTranscriptional control and RNA species - Heart92Accumulation of beta-amyloid 1-40 in HF patients: the role of lncRNA BACE1-AS93Role of miR-182 in zebrafish and mouse models of Holt-Oram syndrome94Mir-27 distinctly regulates muscle-enriched transcription factors and growth factors in cardiac and skeletal muscle cells95AF risk factors impair PITX2 expression leading to Wnt-microRNA-ion channel remodelingCytokines and cellular inflammation - Heart98Post-infarct survival depends on the interplay of monocytes, neutrophils and interferon gamma in a mouse model of myocardial Infarction99Inflammatory cd11b/c cells play a protective role in compensated cardiac hypertrophy by promoting an orai3-related pro-survival signal100Anti-inflammatory effects of endothelin receptor blockade in the atrial tissue of spontaneously hypertensive rats101Mesenchymal stromal cells reduce NLRP3 inflammasome activity in Coxsackievirus B3-induced myocarditis102Mesenchymal stromal cells modulate monocytes trafficking in Coxsackievirus B3-induced myocarditis103The impact of regulatory T lymphocytes on long-term mortality in patients with chronic heart failure104Temporal dynamics of dendritic cells after ST-elevation myocardial infarction relate with improvement of myocardial functionGrowth factors and neurohormones - Heart107Preconditioning of hypertrophied heart: miR-1 and IGF-1 crosstalk108Modulation of catecholamine secretion from human adrenal chromaffin cells by manipulation of G protein-coupled receptor kinase-2 activity109Evaluation of cyclic adenosin-3,5- monophosphate and neurohormones in patients with chronic heart failureNitric oxide and reactive oxygen species - Heart112Hydrogen sulfide donor inhibits oxidative and nitrosative stress, cardiohemodynamics disturbances and restores cNOS coupling in old rats113Role and mechanisms of action of aldehydes produced by monoamine oxidase A in cardiomyocyte death and heart failure114Exercise training has contrasting effects in myocardial infarction and pressure-overload due to different endothelial nitric oxide synthase regulation115S-Nitroso Human Serum Albumin dose-dependently leads to vasodilation and alters reactive hyperaemia in coronary arteries of an isolated mouse heart model116Modulating endothelial nitric oxide synthase with folic acid attenuates doxorubicin-induced cardiomyopathy119Effects of long-term very high intensity exercise on aortic structure and function in an animal model120Electron paramagnetic resonance spectroscopy quantification of nitrosylated hemoglobin (HbNO) as an index of vascular nitric oxide bioavailability in vivo121Deletion of repressor activator protein 1 impairs acetylcholine-induced relaxation due to production of reactive oxygen speciesExtracellular matrix and fibrosis - Heart124MicroRNA-19b is associated with myocardial collagen cross-linking in patients with severe aortic stenosis. Potential usefulness as a circulating biomarker125A new ex vivo model to study cardiac fibrosis126Heterogeneity of fibrosis and fibroblast differentiation in the left ventricle after myocardial infarction127Effect of carbohydrate metabolism degree compensation to the level of galectin-3 changes in hypertensive patients with chronic heart failure and type 2 diabetes mellitus128Statin paradox in association with calcification of bicuspid aortic valve interstitial cells129Cardiac function remains impaired despite reversible cardiac fibrosis after healed experimental viral myocarditisIon channels, ion exchangers and cellular electrophysiology - Heart132Identifying a novel role for PMCA1 (Atp2b1) in heart rhythm instability133Mutations of the caveolin-3 gene as a predisposing factor for cardiac arrhythmias134The human sinoatrial node action potential: time for a computational model135iPSC-derived cardiomyocytes as a model to dissect ion current alterations of genetic atrial fibrillation136Postextrasystolic potentiation in healthy and diseased hearts: effects of the site of origin and coupling interval of the preceding extrasystole137Absence of Nav1.8-based (late) sodium current in rabbit cardiomyocytes and human iPSC-CMs138hiPSC-derived cardiomyocytes from Brugada Syndrome patients without identified mutations do not exhibit cellular electrophysiological abnormalitiesMicrocirculation141Atherogenic indices, collagen type IV turnover and the development of microvascular complications- study in diabetics with arterial hypertension142Changes in the microvasculature and blood viscosity in women with rheumatoid arthritis, hypercholesterolemia and hypertensionAtherosclerosis145Shear stress regulates endothelial autophagy: consequences on endothelial senescence and atherogenesis146Obstructive sleep apnea causes aortic remodeling in a chronic murine model147Aortic perivascular adipose tissue displays an aged phenotype in early and late atherosclerosis in ApoE-/- mice148A systematic evaluation of the cellular innate immune response during the process of human atherosclerosis149Inhibition of Coagulation factor Xa increases plaque stability and attenuates the onset and progression of atherosclerotic plaque in apolipoprotein e-deficient mice150Regulatory CD4+ T cells from patients with atherosclerosis display pro-inflammatory skewing and enhanced suppression function151Hypoxia-inducible factor (HIF)-1alpha regulates macrophage energy metabolism by mediating miRNAs152Extracellular S100A4 is a key player of smooth muscle cell phenotypic transition: implications in atherosclerosis153Microparticles of healthy origins improve atherosclerosis-associated endothelial progenitor cell dysfunction via microRNA transfer154Arterial remodeling and metabolism impairment in early atherosclerosis155Role of pannexin1 in atherosclerotic plaque formationCalcium fluxes and excitation-contraction coupling158Amphiphysin II induces tubule formation in cardiac cells159Interleukin 1 beta regulation of connexin 43 in cardiac fibroblasts and the effects of adult cardiac myocyte:fibroblast co-culture on myocyte contraction160T-tubular electrical defects contribute to blunted beta-adrenergic response in heart failure161Beat-to-beat variability of intracellular Ca2+ dynamics of Purkinje cells in the infarct border zone of the mouse heart revealed by rapid-scanning confocal microscopy162The efficacy of late sodium current blockers in hypertrophic cardiomyopathy is dependent on genotype: a study on transgenic mouse models with different mutations163Synthesis of cADPR and NAADP by intracellular CD38 in heart: role in inotropic and arrhythmogenic effects of beta-adrenoceptor signalingContractile apparatus166Towards an engineered heart tissue model of HCM using hiPSC expressing the ACTC E99K mutation167Diastolic mechanical load delays structural and functional deterioration of ultrathin adult heart slices in culture168Structural investigation of the cardiac troponin complex by molecular dynamics169Exercise training restores myocardial and oxidative skeletal muscle function from myocardial infarction heart failure ratsOxygen sensing, ischaemia and reperfusion172A novel antibody specific to full-length stromal derived factor-1 alpha reveals that remote conditioning induces its cleavage by endothelial dipeptidyl peptidase 4173Attenuation of myocardial and vascular arginase activity by vagal nerve stimulation via a mechanism involving alpha-7 nicotinic receptor during cardiac ischemia and reperfusion174Novel nanoparticle-mediated medicine for myocardial ischemia-reperfusion injury simultaneously targeting mitochondrial injury and myocardial inflammation175Acetylcholine plays a key role in myocardial ischaemic preconditioning via recruitment of intrinsic cardiac ganglia176The role of nitric oxide and VEGFR-2 signaling in post ischemic revascularization and muscle recovery in aged hypercholesterolemic mice177Efficacy of ischemic preconditioning to protect the human myocardium: the role of clinical conditions and treatmentsCardiomyopathies and fibrosis180Plakophilin-2 haploinsufficiency leads to impaired canonical Wnt signaling in ARVC patient181Improved technique for customized, easier, safer and more reliable transverse aortic arch banding and debanding in mice as a model of pressure overload hypertrophy182Late sodium current inhibitors for the treatment of inducible obstruction and diastolic dysfunction in hypertrophic cardiomyopathy: a study on human myocardium183Angiotensin II receptor antagonist fimasartan has protective role of left ventricular fibrosis and remodeling in the rat ischemic heart184Role of High-Mobility Group Box 1 (HMGB1) redox state on cardiac fibroblasts activities and heart function after myocardial infarction185Atrial remodeling in hypertrophic cardiomyopathy: insights from mouse models carrying different mutations in cTnT186Electrophysiological abnormalities in ventricular cardiomyocytes from a Maine Coon cat with hypertrophic cardiomyopathy: effects of ranolazine187ZBTB17 is a novel cardiomyopathy candidate gene and regulates autophagy in the heart188Inhibition of SRSF4 in cardiomyocytes induces left ventricular hypertrophy189Molecular characterization of a novel cardiomyopathy related desmin frame shift mutation190Autonomic characterisation of electro-mechanical remodeling in an in-vitro leporine model of heart failure191Modulation of Ca2+-regulatory function by three novel mutations in TNNI3 associated with severe infant restrictive cardiomyopathyAging194The aging impact on cardiac mesenchymal like stromal cells (S+P+)195Reversal of premature aging markers after bariatric surgery196Sex-associated differences in vascular remodeling during aging: role of renin-angiotensin system197Role of the receptor for advanced glycation end-products (RAGE) in age dependent left ventricle dysfunctionsGenetics and epigenetics200hsa-miR-21-5p as a key factor in aortic remodeling during aneurysm formation201Co-inheritance of mutations associated with arrhythmogenic and hypertrophic cardiomyopathy in two Italian families202Lamin a/c hot spot codon 190: form various amino acid substitutions to clinical effects203Treatment with aspirin and atorvastatin attenuate cardiac injury induced by rat chest irradiation: Implication of myocardial miR-1, miR-21, connexin-43 and PKCGenomics, proteomics, metabolomics, lipidomics and glycomics206Differential phosphorylation of desmin at serines 27 and 31 drives the accumulation of preamyloid oligomers in heart failure207Potential role of kinase Akt2 in the reduced recovery of type 2 diabetic hearts subjected to ischemia / reperfusion injury208A proteomics comparison of extracellular matrix remodelling in porcine coronary arteries upon stent implantationMetabolism, diabetes mellitus and obesity211Targeting grk2 as therapeutic strategy for cancer associated to diabetes212Effects of salbutamol on large arterial stiffness in patients with metabolic syndrome213Circulating microRNA-1 and microRNA-133a: potential biomarkers of myocardial steatosis in type 2 diabetes mellitus214Anti-inflammatory nutrigenomic effects of hydroxytyrosol in human adipocytes - protective mechanisms of mediterranean diets in obesity-related inflammation215Alterations in the metal content of different cardiac regions within a rat model of diabetic cardiomyopathyTissue engineering218A novel conductive patch for application in cardiac tissue engineering219Establishment of a simplified and improved workflow from neonatal heart dissociation to cardiomyocyte purification and characterization220Effects of flexible substrate on cardiomyocytes cell culture221Mechanical stretching on cardiac adipose progenitors upregulates sarcomere-related genes. Cardiovasc Res 2016. [DOI: 10.1093/cvr/cvw135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
37
|
van Setten J, de Jonge N, Holmes M, Khush K, Sweitzer N, Garcia-Pavia P, Rossano J, Dries D, Potena L, Zuckermann A, Christie J, Wilkes D, Lederer D, Meyer K, Glanville A, Corris P, Fisher A, Palmer S, Belperio J, de Weger R, Otten H, van de Graaf E, Keating B, Asselbergs F. The Role of Loss-of-Function Mutations on Death and Development of Rejection in HTX/LTX Patients. J Heart Lung Transplant 2016. [DOI: 10.1016/j.healun.2016.01.535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
38
|
Gonzalez-Valdes I, Hidalgo I, Bujarrabal A, Lara-Pezzi E, Padron-Barthe L, Garcia-Pavia P, Gómez-del Arco P, Gomez P, Redondo JM, Ruiz-Cabello JM, Jimenez-Borreguero LJ, Enriquez JA, de la Pompa JL, Hidalgo A, Gonzalez S. Bmi1 limits dilated cardiomyopathy and heart failure by inhibiting cardiac senescence. Nat Commun 2015; 6:6473. [PMID: 25751743 PMCID: PMC5603726 DOI: 10.1038/ncomms7473] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2014] [Accepted: 01/30/2015] [Indexed: 12/14/2022] Open
Abstract
Dilated cardiomyopathy (DCM) is the most frequent cause of heart failure and the leading indication for heart transplantation. Here we show that epigenetic regulator and central transcriptional instructor in adult stem cells, Bmi1, protects against DCM by repressing cardiac senescence. Cardiac-specific Bmi1 deletion induces the development of DCM, which progresses to lung congestion and heart failure. In contrast, Bmi1 overexpression in the heart protects from hypertrophic stimuli. Transcriptome analysis of mouse and human DCM samples indicates that p16INK4a derepression, accompanied by a senescence-associated secretory phenotype (SASP), is linked to severely impaired ventricular dimensions and contractility. Genetic reduction of p16INK4a levels reverses the pathology of Bmi1-deficient hearts. In parabiosis assays, the paracrine senescence response underlying the DCM phenotype does not transmit to healthy mice. As senescence is implicated in tissue repair and the loss of regenerative potential in aging tissues, these findings suggest a source for cardiac rejuvenation. The epigenetic factor Bmi1 regulates self-renewal of many adult stem cells, but its role in heart function is unknown. Here the authors show that Bmi1 prevents cardiac senescence by inhibiting the tumor suppressor protein p16INK4a in adult mice, protecting them from dilated cardiomyopathy and heart failure.
Collapse
Affiliation(s)
- I Gonzalez-Valdes
- Stem Cell Aging Group, Centro Nacional de Investigaciones Cardiovasculares (CNIC), E-28029 Madrid, Spain
| | - I Hidalgo
- Stem Cell Aging Group, Centro Nacional de Investigaciones Cardiovasculares (CNIC), E-28029 Madrid, Spain
| | - A Bujarrabal
- Stem Cell Aging Group, Centro Nacional de Investigaciones Cardiovasculares (CNIC), E-28029 Madrid, Spain
| | - E Lara-Pezzi
- Molecular Regulation of Heart Development and Disease Group, Centro Nacional de Investigaciones Cardiovasculares (CNIC), E-28029 Madrid, Spain
| | - L Padron-Barthe
- 1] Molecular Regulation of Heart Development and Disease Group, Centro Nacional de Investigaciones Cardiovasculares (CNIC), E-28029 Madrid, Spain [2] Heart Failure and Inherited Cardiac Diseases Unit, Hospital Universitario Puerta de Hierro Majadahonda, Manuel de Falla, 1, E-28222 Madrid, Spain
| | - P Garcia-Pavia
- Heart Failure and Inherited Cardiac Diseases Unit, Hospital Universitario Puerta de Hierro Majadahonda, Manuel de Falla, 1, E-28222 Madrid, Spain
| | | | - P Gomez
- Gene Regulation in Cardiovascular Remodelling and Inflammation Group, Centro Nacional de Investigaciones Cardiovasculares (CNIC), E-28029 Madrid, Spain
| | - J M Redondo
- Gene Regulation in Cardiovascular Remodelling and Inflammation Group, Centro Nacional de Investigaciones Cardiovasculares (CNIC), E-28029 Madrid, Spain
| | - J M Ruiz-Cabello
- Advanced Imaging Unit, Ciber de Enfermedades respiratorias and UCM, Centro Nacional de Investigaciones Cardiovasculares (CNIC), E-28029 Madrid, Spain
| | - L J Jimenez-Borreguero
- Advanced Imaging Unit, Ciber de Enfermedades respiratorias and UCM, Centro Nacional de Investigaciones Cardiovasculares (CNIC), E-28029 Madrid, Spain
| | - J A Enriquez
- Functional Genetics of the Oxidative Phosphorylation System, Centro Nacional de Investigaciones Cardiovasculares (CNIC), E-28029 Madrid, Spain
| | - J L de la Pompa
- Intercellular Signaling In Cardiovascular Development and Disease Group, Centro Nacional de Investigaciones Cardiovasculares (CNIC), E-28029 Madrid, Spain
| | - A Hidalgo
- Imaging the Cardiovascular Inflammation and the Immune Response, Centro Nacional de Investigaciones Cardiovasculares (CNIC), E-28029 Madrid, Spain
| | - S Gonzalez
- Stem Cell Aging Group, Centro Nacional de Investigaciones Cardiovasculares (CNIC), E-28029 Madrid, Spain
| |
Collapse
|
39
|
Risum N, Tayal B, Fritz Hansen T, Bruun N, Saba S, Kisslo J, Gorcsan J, Sogaard P, Venner C, Selton-Suty C, Huttin O, Voilliot D, Marie P, Aliot E, Juilliere Y, Tsukishiro Y, Onishi T, Matsuyama S, Chimura M, Yamada S, Taniguchi Y, Yasaka Y, Kawai H, Reant P, Mirabel M, Dickie S, Rosmini S, Demetrescu C, Tome-Esteban M, Moon J, Lafitte S, Elliott P, Mckenna W, Ozawa K, Funabashi N, Takaoka H, Kobayashi Y, Zegri Reiriz I, Alcolado A, Mendez C, Sanchez M, Gomez Y, Climent V, Ripoll T, Montserrat L, Gimeno J, Garcia-Pavia P, Hu K, Liu D, Cikes M, Stoerk S, Kramer B, Gaudron P, Ertl G, Bijnens B, Weidemann F, Herrmann S, Kagiyama N, Okura H, Yamada R, Kume T, Neishi Y, Ohara M, Hayashida A, Hirohata A, Yamamoto K, Yoshida K, Sade LE, Kozan H, Eroglu S, Pirat B, Sezgin A, Aydinalp A, Muderrisoglu H, Agricola E, Spoladore R, Ballarotto M, Fisicaro A, Marcatti M, Margonato A, Camici P. MODERATED POSTER SESSION: Imaging in cardiomyopathies: Friday 5 December 2014, 08:30-18:00 * Location: Moderated Poster area. Eur Heart J Cardiovasc Imaging 2014. [DOI: 10.1093/ehjci/jeu264] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
40
|
Goirigolzarri Artaza J, Gallego Delgado M, Jaimes Castellanos C, Cavero Gibanel M, Pastrana Ledesma M, Alonso Pulpon L, Gonzalez Mirelis J, Al Ansi RZ, Sokolovic S, Cerin G, Szychta W, Popa BA, Botezatu D, Benea D, Manganiello S, Corlan A, Jabour A, Igual Munoz B, Osaca Asensi J, Andres La Huerta A, Maceira Gonzalez A, Estornell Erill J, Cano Perez O, Sancho-Tello M, Alonso Fernandez P, Sepulveda Sanchez P, Montero Argudo A, Palombo C, Morizzo C, Baluci M, Kozakova M, Panajotu A, Karady J, Szeplaki G, Horvath T, Tarnoki D, Jermendy A, Geller L, Merkely B, Maurovich-Horvat P, Moustafa S, Mookadam F, Youssef M, Zuhairy H, Connelly M, Prieur T, Alvarez N, Ashikhmin Y, Drapkina O, Boutsikou M, Demerouti E, Leontiadis E, Petrou E, Karatasakis G, Kozakova M, Morizzo C, Bianchi V, Marchi B, Federico G, Palombo C, Chatzistamatiou E, Moustakas G, Memo G, Konstantinidis D, Mpampatzeva Vagena I, Manakos K, Traxanas K, Vergi N, Feretou A, Kallikazaros I, Goto M, Uejima T, Itatani K, Pedrizzetti G, Mada R, Daraban A, Duchenne J, Voigt J, Chiu DYY, Green D, Johnstone L, Sinha S, Kalra P, Abidin N, Sikora-Frac M, Zaborska B, Maciejewski P, Bednarz B, Budaj A, Nemes A, Sasi V, Gavaller H, Kalapos A, Domsik P, Katona A, Szucsborus T, Ungi T, Forster T, Ungi I, Pluchinotta F, Arcidiacono C, Saracino A, Carminati M, Bussadori C, Dahlslett T, Karlsen S, Grenne B, Sjoli B, Bendz B, Skulstad H, Smiseth O, Edvardsen T, Brunvand H, Vereckei A, Szelenyi Z, Szenasi G, Santoro C, Galderisi M, Niglio T, Santoro M, Stabile E, Rapacciuolo A, Spinelli L, De Simone G, Esposito G, Trimarco B, Hubert S, Jacquier A, Fromonot J, Resseguier C, Tessier A, Guieu R, Renard S, Haentjiens J, Lavoute C, Habib G, Menting ME, Koopman L, Mcghie J, Rebel B, Gnanam D, Helbing W, Van Den Bosch A, Roos-Hesselink J, Shiino K, Yamada A, Sugimoto K, Takada K, Takakuwa Y, Miyagi M, Iwase M, Ozaki Y, Hayashi T, Itatani K, Inuzuka R, Shindo T, Hirata Y, Shimizu N, Miyaji K, Henri C, Dulgheru R, Magne J, Kou S, Davin L, Nchimi A, Oury C, Pierard L, Lancellotti P, Kovalyova O, Honchar O, Tengku W, Ketaren A, Mingo Santos S, Monivas Palomero V, Restrepo Cordoba A, Rodriguez Gonzalez E, Goirigolzarri Artaza J, Sayago Silva I, Garcia Lunar I, Mitroi C, Cavero Gibanel M, Segovia Cubero J, Ryu S, Park J, Kim S, Choi J, Goh C, Byun Y, Choi J, Westholm C, Johnson J, Jernberg T, Winter R, Rio P, Moura Branco L, Galrinho A, Pinto Teixeira P, Viveiros Monteiro A, Portugal G, Pereira-Da-Silva T, Afonso Nogueira M, Abreu J, Cruz Ferreira R, Mazzone A, Botto N, Paradossi U, Chabane A, Francini M, Cerone E, Baroni M, Maffei S, Berti S, Ghattas A, Shantsila E, Griffiths H, Lip G, Galli E, Guirette Y, Daudin M, Auffret V, Mabo P, Donal E, Fabiani I, Conte L, Scatena C, Barletta V, Pratali S, De Martino A, Bortolotti U, Naccarato A, Di Bello V, Falanga G, Alati E, Di Giannuario G, Zito C, Cusma' Piccione M, Carerj S, Oreto G, Dattilo G, Alfieri O, La Canna G, Generati G, Bandera F, Pellegrino M, Alfonzetti E, Labate V, Guazzi M, Cengiz B, Sahin ST, Yurdakul S, Kahraman S, Bozkurt A, Aytekin S, Borges IP, Peixoto E, Peixoto R, Peixoto R, Marcolla V, Venkateshvaran A, Sola S, Dash PK, Thapa P, Manouras A, Winter R, Brodin L, Govind SC, Mizariene V, Verseckaite R, Bieseviciene M, Karaliute R, Jonkaitiene R, Vaskelyte J, Arzanauskiene R, Janenaite J, Jurkevicius R, Rosner S, Orban M, Nadjiri J, Lesevic H, Hadamitzky M, Sonne C, Manganaro R, Carerj S, Cusma-Piccione M, Caprino A, Boretti I, Todaro M, Falanga G, Oreto L, D'angelo M, Zito C, Le Tourneau T, Cueff C, Richardson M, Hossein-Foucher C, Fayad G, Roussel J, Trochu J, Vincentelli A, Cavalli G, Muraru D, Miglioranza M, Addetia K, Veronesi F, Cucchini U, Mihaila S, Tadic M, Lang R, Badano L, Polizzi V, Pino P, Luzi G, Bellavia D, Fiorilli R, Chialastri C, Madeo A, Malouf J, Buffa V, Musumeci F, Gripari P, Tamborini G, Bottari V, Maffessanti F, Carminati C, Muratori M, Vignati C, Bartorelli A, Alamanni F, Pepi M, Polymeros S, Dimopoulos A, Spargias K, Karatasakis G, Athanasopoulos G, Pavlides G, Dagres N, Vavouranakis E, Stefanadis C, Cokkinos D, Pradel S, Mohty D, Magne J, Darodes N, Lavergne D, Damy T, Beaufort C, Aboyans V, Jaccard A, Mzoughi K, Zairi I, Jabeur M, Ben Moussa F, Ben Chaabene A, Kamoun S, Mrabet K, Fennira S, Zargouni A, Kraiem S, Jovanova S, Arnaudova-Dezjulovic F, Correia CE, Cruz I, Marques N, Fernandes M, Bento D, Moreira D, Lopes L, Azevedo O, Keramida K, Kouris N, Kostopoulos V, Psarrou G, Giannaris V, Olympios C, Marketou M, Parthenakis F, Kalyva N, Pontikoglou C, Maragkoudakis S, Zacharis E, Patrianakos A, Roufas K, Papadaki H, Vardas P, Dominguez Rodriguez F, Monivas Palomero V, Mingo Santos S, Arribas Rivero B, Cuenca Parra S, Zegri Reiriz I, Vazquez Lopez-Ibor J, Garcia-Pavia P, Szulik M, Streb W, Wozniak A, Lenarczyk R, Sliwinska A, Kalarus Z, Kukulski T, Nemes A, Domsik P, Kalapos A, Forster T, Serra W, Lumetti F, Mozzani F, Del Sante G, Ariani A, Corros C, Colunga S, Garcia-Campos A, Diaz E, Martin M, Rodriguez-Suarez M, Leon V, Fidalgo A, Moris C, De La Hera J, Kylmala MM, Rosengard-Barlund M, Groop PH, Lommi J, Bruin De- Bon H, Bilt Van Der I, Wilde A, Brink Van Den R, Teske A, Rinkel G, Bouma B, Teixeira R, Monteiro R, Garcia J, Silva A, Graca M, Baptista R, Ribeiro M, Cardim N, Goncalves L, Duszanska A, Skoczylas I, Kukulski T, Polonski L, Kalarus Z, Choi JH, Park J, Ahn J, Lee J, Ryu S, Ahn J, Kim D, Lee H, Przewlocka-Kosmala M, Mlynarczyk J, Rojek A, Mysiak A, Kosmala W, Pellissier A, Larochelle E, Krsticevic L, Baron E, Le V, Roy A, Deragon A, Cote M, Garcia D, Tournoux F, Yiangou K, Azina C, Yiangou A, Zitti M, Ioannides M, Ricci F, Dipace G, Aquilani R, Radico F, Cicchitti V, Bianco F, Miniero E, Petrini F, De Caterina R, Gallina S, Jardim Prista Monteiro R, Teixeira R, Garcia J, Baptista R, Ribeiro M, Cardim N, Goncalves L, Chung H, Kim J, Joung B, Uhm J, Pak H, Lee M, Lee K, Ragab A, Abdelwahab A, Yazeed Y, El Naggar W, Spahiu K, Spahiu E, Doko A, Liesting C, Brugts J, Kofflard M, Kitzen J, Boersma E, Levin MD, Coppola C, Piscopo G, Rea D, Maurea C, Caronna A, Capasso I, Maurea N, Azevedo O, Tadeu I, Lourenco M, Portugues J, Pereira V, Lourenco A, Nesukay E, Kovalenko V, Cherniuk S, Danylenko O, Nemes A, Domsik P, Kalapos A, Lengyel C, Varkonyi T, Orosz A, Forster T, Castro M, Abecasis J, Dores H, Madeira S, Horta E, Ribeiras R, Canada M, Andrade M, Mendes M, Morosin M, Piazza R, Leonelli V, Leiballi E, Pecoraro R, Cinello M, Dell' Angela L, Cassin M, Sinagra G, Nicolosi G, Wierzbowska-Drabik K, Hamala P, Kasprzak J, O'driscoll J, Rossato C, Gargallo-Fernandez P, Araco M, Sharma S, Sharma R, Jakus N, Baricevic Z, Ljubas Macek J, Skoric B, Skorak I, Velagic V, Separovic Hanzevacki J, Milicic D, Cikes M, Deljanin Ilic M, Ilic S, Kocic G, Pavlovic R, Stoickov V, Ilic V, Nikolic L, Generati G, Bandera F, Pellegrino M, Alfonzetti E, Labate V, Guazzi M, Labate V, Bandera F, Generati G, Pellegrino M, Donghi V, Alfonzetti E, Guazzi M, Zakarkaite D, Kramena R, Aidietiene S, Janusauskas V, Rucinskas K, Samalavicius R, Norkiene I, Speciali G, Aidietis A, Kemaloglu Oz T, Ozpamuk Karadeniz F, Akyuz S, Unal Dayi S, Esen Zencirci A, Atasoy I, Osken A, Eren M, Fazendas PR, Caldeira D, Stuart B, Cruz I, Rocha Lopes L, Almeida AR, Sousa P, Joao I, Cotrim C, Pereira H, Fazendas PR, Caldeira D, Stuart B, Cruz I, Rocha Lopes L, Almeida AR, Joao I, Cotrim C, Pereira H, Sinem Cakal S, Elif Eroglu E, Baydar O, Beytullah Cakal B, Mehmet Vefik Yazicioglu M, Mustafa Bulut M, Cihan Dundar C, Kursat Tigen K, Birol Ozkan B, Ali Metin Esen A, Yagasaki H, Kawasaki M, Tanaka R, Minatoguchi S, Houle H, Warita S, Ono K, Noda T, Watanabe S, Minatoguchi S, Cho EJ, Park SJ, Lim HJ, Chang SA, Lee SC, Park SW, Cho EJ, Park SJ, Lim HJ, Chang SA, Lee SC, Park SW, Mornos C, Cozma D, Ionac A, Mornos A, Popescu I, Ionescu G, Pescariu S, Melzer L, Faeh-Gunz A, Seifert B, Attenhofer Jost CH, Storve S, Haugen B, Dalen H, Grue J, Samstad S, Torp H, Ferrarotti L, Maggi E, Piccinino C, Sola D, Pastore F, Marino P, Ranjbar S, Karvandi M, Hassantash S, Karvandi M, Ranjbar S, Tierens S, Remory I, Bala G, Gillis K, Hernot S, Droogmans S, Cosyns B, Lahoutte T, Tran N, Poelaert J, Al-Mallah M, Alsaileek A, Nour K, Celeng C, Horvath T, Kolossvary M, Karolyi M, Panajotu A, Kitslaar P, Merkely B, Maurovich Horvat P, Aguiar Rosa S, Ramos R, Marques H, Portugal G, Pereira Da Silva T, Rio P, Afonso Nogueira M, Viveiros Monteiro A, Figueiredo L, Cruz Ferreira R. Poster session 6. Eur Heart J Cardiovasc Imaging 2014; 15:ii235-ii264. [PMCID: PMC4453635 DOI: 10.1093/ehjci/jeu271] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 08/13/2023] Open
|
41
|
Dominguez Rodriguez F, Mingo Santos S, Monivas Palomero V, Garcia Lunar I, Garcia-Pavia P, Cuenca Parra S, Zegri Reiriz I, Cavero Gibanel MA. 2D Strain in left ventricular non compaction: the clue for differential diagnosis with hypertrophic cardiomyopathy. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht309.p2995] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
42
|
Garcia-Pavia P, Guzzo Merello G, Cobo M, Segovia J, Gomez-Bueno M, Bornstein B, Alonso-Pulpon L. Prevalence of Lamin A/C mutations and digenetic Lamin A/C and desmosomal genes mutations among idiopathic dilated cardiomyopathy heart transplant recipients. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht309.p4234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Badagliacca R, Reali M, Vizza C, Poscia R, Pezzuto B, Gambardella C, Papa S, Mezzapesa M, Nocioni M, Fedele F, Freed B, Bhave N, Tsang W, Gomberg-Maitland M, Mor-Avi V, Patel A, Lang RM, Liel-Cohen N, Yaacobi M, Guterman H, Jurzak P, Ternacle J, Gallet R, Bensaid A, Kloeckner M, Monin JL, Gueret P, Dubois-Rande JL, Lim P, Otsuka T, Suzuki M, Yoshikawa H, Hashimoto G, Ishikawa Y, Osaki T, Masai H, Ono T, Yamamoto M, Sugi K, Satendra M, Sargento L, Sousa C, Arsenio A, Lousada N, Palma Reis R, Wang S, Lam Y, Liu M, Fang F, Shang Q, Luo X, Wang J, Sun J, Sanderson J, Yu C, De Marchi S, Hopp E, Urheim S, Hervold A, Murbrach K, Massey R, Remme E, Hol P, Aakhus S, Bouzas Mosquera A, Peteiro J, Broullon F, Garcia NA, Rodriguez Garrido J, Martinez Ruiz D, Yanez Wonenburger J, Bouzas Zubeldia B, Fabregas Casal R, Castro Beiras A, Le Tourneau T, Sportouch C, Foucher C, Delasalle B, Rosso J, Neuder Y, Trochu J, Roncalli J, Lemarchand P, Manrique A, Sharif D, Sharif-Rasslan A, Shahla C, Khalil A, Rosenschein U, Monti L, Tramarin M, Calcagnino M, Lisignoli V, Nardi B, Balzarini L, Khalatbari A, Mills J, Chenzbraun A, Theron A, Morera P, Resseguier N, Thuny F, Riberi A, Giorgi R, Collart F, Habib G, Avierinos J, Liu D, Hu K, Niemann M, Herrmann S, Gaudron P, Voelker W, Ertl G, Bijnens B, Weidemann F, Lenders GD, Bosmans JM, Van Herck PL, Rodrigus IE, Claeys MJ, Vrints CJ, Paelinck BP, Veronesi F, Fusini L, Tamborini G, Gripari P, Maffessanti F, Mirea O, Alamanni F, Pepi M, Caiani E, Frikha Z, Zairi I, Saib W, Fennira S, Ben Moussa F, Kammoun S, Mrabet K, Ben Yaala A, Said L, Ghannouchi M, Carlomagno G, Ascione L, Sordelli C, Iengo R, Severino S, D'andrea A, Calabro' R, Caso P, Mizia M, Mizia-Stec K, Sikora-Puz A, Gieszczyk-Strozik K, Chmiel A, Haberka M, Hudziak D, Jasinski M, Gasior Z, Wos S, Biaggi P, Felix C, Gruner C, Hohlfeld S, Herzog B, Gaemperli O, Gruenenfelder J, Corti R, Tanner F, Bettex D, Kovalova S, Necas J, Dominguez Rodriguez F, Monivas V, Mingo S, Garcia-Lunar I, Garcia-Pavia P, Gonzalez-Mirelis J, Zegri I, Cavero M, Jeon HK, Lee D, Youn H, Shin H, Yoon J, Chung H, Choi E, Kim J, Min P, Lee B, Yoon Y, Hong B, Kwon H, Rim S, Petronilli V, Cimino S, De Luca L, Cicogna F, Arcari L, Francone M, Iacoboni C, Agati L, Halmai L, Atkinson P, Kardos A, Bogle R, Meimoun P, Flahaut G, Charles V, Villain Y, Clerc J, Germain A, Elmkies F, Zemir H, Luycx-Bore A, Kim K, Song J, Jeong H, Yoon H, Ahn Y, Jeong M, Cho J, Park J, Kang J, Tolba OA, El-Shanshory MR, El-Shitany NAEA, El-Hawary ES, Elkilany GN, Tolba OA, El-Shanshory MR, El-Shitany AEA, El-Hawary EES, Nagib Elkilany GE, Costanzo L, Buccheri S, Monte IP, Curatolo G, Crapanzano P, Di Pino L, Rodolico M, Blundo A, Leggio S, Tamburino C, Rees E, Hocking R, Dunstan F, Lewis M, Tunstall K, Rees DA, Halcox JP, Fraser AG, Rodrigues A, Guimaraes L, Guimaraes J, Monaco C, Cordovil A, Lira E, Vieira M, Fischer C, Nomura C, Morhy S, Bruno R, Cogo A, Sharma R, Bartesaghi M, Pomidori L, Basnyat B, Taddei S, Picano E, Sicari R, Pratali L, Satendra M, Sargento L, Sousa C, Lousada N, Palma Reis R, Zakhama L, Sioua S, Naffati S, Marouen A, Boussabah E, Kadour R, Thameur M, Benyoussef S, Vanoli D, Wiklund U, Henein M, Naslund U, Lindqvist P, Palinsky M, Petrovicova J, Pirscova M, Korpi K, Blafield H, Suomi H, Linden P, Valtonen M, Jarvinen V, Laine M, Loimaala A, Kaldararova M, Kantorova A, Vrsanska V, Tittel P, Hraska V, Masura J, Simkova I, Attenhofer Jost C, Zimmermann C, Greutmann M, Dave H, Valsangiacomo Buechel E, Pretre R, Mueller C, Seifert B, Kretschmar O, Weber R, Carro A, Teixido G, Rodriguez-Palomares J, Gutierrez L, Maldonado G, Paucca E, Gonzalez-Alujas T, Evangelista A, Al Akhfash A, Al Mesned D, Maan Hasson D, Al Harbi B M, Cruz C, Pinho T, Lebreiro A, Silva Cardoso J, Julia Maciel M, Kalimanovska-Ostric D, Nastasovic T, Deljanin-Ilic M, Milakovic B, Dostanic M, Stosic M, Lam YY, Fang F, Yu C, Bobbo M, Leonelli V, Piazza R, Leiballi E, Pecoraro R, Cinello M, Mimo R, Cervesato E, Nicolosi GL, Cruz C, Pinho T, Lebreiro A, Silva Cardoso J, Julia Maciel M, Moral Torres S, Evangelista A, Gonzalez-Alujas M, Rodriguez-Palomares J, Teixido G, Gutierrez L, Cuellar H, Carro A, Maldonado G, Garcia-Dorado D, Kocabay G, Dal Bianco L, Muraru D, Peluso D, Segafredo B, Iliceto S, Badano L, Schiano Lomoriello V, Santoro A, Esposito R, Ippolito R, De Palma D, Schiattarella P, Muscariello R, Galderisi M, Teixido Tura G, Redheuil A, Rodriguez-Palomares J, Gutierrez L, Sanchez V, Forteza A, Lima J, Garcia-Dorado D, Evangelista A, Moral Torres S, Evangelista A, Gonzalez-Alujas M, Rodriguez-Palomares J, Teixido G, Gutierrez L, Cuellar H, Carro A, Maldonado G, Garcia-Dorado D, Mihalcea D, Florescu M, Suran B, Enescu O, Mincu R, Patrascu N, Serbanoiu I, Margulescu A, Vinereanu D, Teixido Tura G, Rodriguez-Palomares J, Gutierrez L, Gonzalez-Alujas T, Carro A, Thomas M, Garcia-Dorado D, Evangelista A, Tosello F, Milan A, Magnino C, Leone D, Chiarlo M, Bruno G, Losano I, Burrello J, Fulcheri C, Veglio F, Styczynski G, Szmigielski CA, Kaczynska A, Kuch-Wocial A, Jansen R, Kracht P, Kluin J, Tietge W, Cramer M, Chamuleau S, Zito C, Tripepi S, Cusma-Piccione M, Di Bella G, Mohammed M, Oreto L, Manganaro R, D'angelo M, Pizzino F, Carerj S, Arapi S, Tsounis D, Matzraki V, Kaplanis I, Perpinia A, Varoudi M, Mpitsios G, Lazaros G, Karavidas A, Pyrgakis V, Mornos C, Ionac A, Cozma D, Mornos A, Dragulescu D, Petrescu L, Pescariu S, Lupinek P, Sramko M, Kubanek M, Kautznerova D, Tintera J, Lanska V, Kadrabulatova S, Pavlukova E, Tarasov D, Karpov R, Sveric K, Forkmann M, Richter U, Wunderlich C, Strasser R, Grapsa J, Dawson D, Zimbarra Cabrita I, Punjabi P, Nihoyannopoulos P, Kovacs A, Apor A, Nagy A, Vago H, Toth A, Becker D, Merkely B, Ranjbar S, Karvandi M, Hassantash S, Yoshikawa H, Suzuki M, Kusunose Y, Hashimoto G, Otsuka T, Nakamura M, Sugi K, De Knegt M, Biering-Sorensen T, Sogaard P, Sivertsen J, Jensen J, Mogelvang R, Montserrat S, Gabrielli L, Borras R, Bijnens B, Castella M, Berruezo A, Mont L, Brugada J, Sitges M, Tarr A, Stoebe S, Pfeiffer D, Hagendorff A, Ternacle J, Jurzak P, Gallet R, Champagne S, Teiger E, Monin JL, Gueret P, Dubois-Rande JL, Lim P, Monney P, Jeanrenaud X, Monivas Palomero V, Mingo Santos S, Garcia Lunar I, Beltran Correas P, Gonzalez Lopez E, Sanchez Garcia M, Gonzalez Mirelis J, Cavero Gibanel M, Gomez Bueno M, Segovia Cubero J, Haarman M, Van Den Bosch A, Domburg R, Mcghie J, Roos-Hesselink J, Geleijnse M, Yanikoglu A, Altekin E, Kucuk M, Karakas S, Ozel D, Yilmaz H, Demir I, Tsuruta H, Iwanaga S, Sato T, Miyoshi S, Nishiyama N, Aizawa Y, Tanimoto K, Murata M, Takatsuki S, Fukuda K, Carrilho-Ferreira P, Cortez-Dias N, Silva D, Jorge C, Goncalves S, Santos I, Sargento L, Marques P, Carpinteiro L, Sousa J, Schubert U, Kockova R, Tintera J, Kautznerova D, Cerna D, Sedlacek K, Kryze L, Sikula V, Segetova M, Kautzner J, Iwaki T, Dores H, Goncalves P, Sousa P, Carvalho M, Marques H, Machado F, Gaspar A, Aleixo A, Carmo M, Roquette J, Lagopati N, Sotiropoulos M, Baka I, Ploussi A, Lyra Georgosopoulou M, Miglioranza M, Gargani L, Sant'anna R, Rover M, Mantovani A, Kalil R, Sicari R, Picano E, Leiria T, Minarik T, Taborsky M, Fedorco M, Novak P, Ledakowicz-Polak A, Polak L, Zielinska M, Zhong L, Chin C, Lau Y, Sim L, Chua T, Tan B, Tan R. Poster session: Dobutamine stress echo. Eur Heart J Cardiovasc Imaging 2012. [DOI: 10.1093/ehjci/jes257] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
44
|
Campuzano O, Alcalde M, Berne P, Castro V, Guzzo G, Iglesias A, Alonso-Pulpon L, Garcia-Pavia P, Brugada J, Brugada R. Genetic testing of candidate genes in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Eur J Med Genet 2012; 55:225-34. [PMID: 22421524 DOI: 10.1016/j.ejmg.2012.02.007] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2011] [Accepted: 02/15/2012] [Indexed: 01/02/2023]
Abstract
Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is a rare cardiac genetic disease characterized by the presence of structural alterations in the right ventricle which may cause ventricular arrhythmias and may induce sudden cardiac death. ARVC/D has been associated with mutations in genes encoding myocyte adhesion proteins. However, only 30%-50% of patients have mutations in these genes. Genetic testing is useful in obtaining a diagnosis, particularly in individuals who do not completely fulfill clinical criteria, thereby also enabling the undertaking of preventive strategies in family members. The main goal of this study was to identify mutations in candidate genes associated with intercalate disks that could be potentially involved in ARVC/D pathogenesis. We analyze a cohort of 14 Spanish unrelated patients clinically diagnosed with ARVC/D without any genetic alteration in all previously known responsible genes. Thus, a genetic screening has been performed in 7 additional potential candidate genes (ACTC1 -actin alpha cardiac muscle 1-, CDHN -cadherin 2 type 1 or N-cadherin-, CTNNA1 -catenin alpha 1-, Cx43 or GJA1 -gap junction protein alpha 1-, MVCL -Metavinculin-, MYL2 -myosin light chain 2- and MYL3 -myosin light chain 3-) by direct sequencing analysis. Our genetic analysis did not identify any disease-causing mutation. Thirty single nucleotides polymorphisms were found, six of them novel. In conclusion, our ARVC/D Spanish cohort has not shown any mutations in the analyzed candidate genes despite their involvement in formation and maintenance of the intercalated disk.
Collapse
Affiliation(s)
- O Campuzano
- Cardiovascular Genetics Center, University of Girona-IdIBGi, C/ Pic de Peguera 11, 17003 Girona, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Garcia-Pavia P, Segovia J, Vazquez M, Salas C, Avellana P, Gomez-Bueno M, Gallardo E, Garcia-Cosio Carmena M, Cobo-Marcos M, Vilches C, Garesse R, Molano J, Bornstein B, Alonso Pulpón L. 392 Genetic Basis of Heart Transplanted Hypertrophic Cardiomyopathy. J Heart Lung Transplant 2011. [DOI: 10.1016/j.healun.2011.01.400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
46
|
Barcelo J, Segovia J, Gomez-Bueno M, Garcia-Pavia P, Cobo M, Sufrate E, Mirelis J, Alonso-Pulpon L. 575: Prognostic Value of Right Ventricular Dysfunction and Pulmonary Artery Hypertension Parameters for Risk Stratification of Patients with Heart Failure. J Heart Lung Transplant 2009. [DOI: 10.1016/j.healun.2008.11.582] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
47
|
Barcelo J, Salas C, Segovia J, Gomez-Bueno M, Garcia-Pavia P, Cobo M, Mirelis J, Alonso-Pulpon L. 340: Coronary Atherosclerosis in Explanted Hearts with Presumed Idiopathic Dilated Cardiomyopathy. J Heart Lung Transplant 2009. [DOI: 10.1016/j.healun.2008.11.347] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
48
|
Segovia J, Barcelo J, Gomez-Bueno M, Gallego-Page J, Cobo M, Mirelis J, Garcia-Pavia P, Alonso-Pulpon L. 500: Influence of Reinnervation after Heart Transplantation on Coronary Allograft Vasculopathy and Cardiovascular Death. J Heart Lung Transplant 2009. [DOI: 10.1016/j.healun.2008.11.890] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|